Endonovo Therapeutics (ENDV) S-1/A 7 Jan 19 IPO registration (amended) Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 30, 2018
Document And Entity Information
Entity Registrant Name	ENDONOVO THERAPEUTICS, INC.
Entity Central Index Key	1,528,172
Document Type	S-1/A
Document Period End Date	Sep. 30, 2018
Amendment Flag	true
Amendment Description	AMENDMENT #1
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Trading Symbol	ENDV

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash	$ 665,244	$ 90,173	$ 55,533
Accounts receivable	2,650
Prepaid expenses and other current assets	21,000	21,000	247,321
Total current assets	688,894	111,173	302,854
Property Plant and Equipment, net	7,741	1,064	15,825
Patents, net	4,014,817	4,500,000
Total assets	4,711,452	4,612,237	318,679
Current Liabilities
Accounts payable and accrued expenses	3,179,602	2,714,041	4,727,247
Short term advances		20,323	5,823
Notes payable, net of discounts of $1,175,627 as of September 30, 2018 and $2,624,984 as of December 31, 2017	6,966,896	4,461,160	1,878,107
Notes payable - related parties	270,000	270,000	170,000
Derivative liability	7,057,172	5,939,600	1,927,752
Current portion of long term loan		4,221	12,395
Total current liabilities	17,473,670	13,409,345	8,721,324
Series C preferred stock liability, net of discounts of $152,972 at September 30, 2018 and $101,808 as of December 31, 2017	1,164,528	598,192
Long term loan			4,221
Acquisition payable	155,000	155,000	155,000
Total liabilities	18,793,198	14,162,537	8,880,545
COMMITMENTS AND CONTINGENCIES, note 9
Shareholders' deficit
Super AA super voting preferred stock, $0.001 par value; 1,000,000 authorized and 5,000 and 5,000 issued and outstanding at September 30, 2018 and December 31, 2017	5	5
Series B convertible preferred stock, $0.0001 par value; 50,000 shares authorized, 1,350 and 0 issued and outstanding at September 30, 2018 and December 31, 2017	1
Common stock, $0.0001 par value; 2,500,000,000 shares authorized; 381,375,857 and 316,951,712 shares issued and outstanding as of Septermber 30, 2018 and December 31, 2017	38,136	31,692	13,434
Additional paid-in capital	22,884,078	19,604,016	9,800,553
Stock subscriptions	(1,570)	(1,570)	(1,570)
Accumulated deficit	(37,002,396)	(29,184,443)	(18,374,283)
Total shareholders' deficit	(14,081,746)	(9,550,300)	(8,561,866)
Total liabilities and shareholders' deficit	$ 4,711,452	$ 4,612,237	$ 318,679

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Discounts on current notes payable	$ 1,175,627	$ 2,624,984	$ 1,145,849
Super AA super voting preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Super AA super voting preferred stock, shares authorized	1,000,000	1,000,000	1,000,000
Super AA super voting preferred stock, shares issued	5,000	5,000	1,000
Super AA super voting preferred stock, shares outstanding	5,000	5,000	1,000
Series B convertible preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Series B convertible preferred stock, shares authorized	50,000	50,000	50,000
Series B convertible preferred stock, shares issued	1,350	0	0
Series B convertible preferred stock, shares outstanding	1,350	0	0
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	2,500,000,000	2,500,000,000	500,000,000
Common stock, shares issued	381,375,857	316,951,712	134,336,637
Common stock, shares outstanding	381,375,857	316,951,712	134,336,637
Series C Preferred Stock [Member]
Series C preferred stock liability, net of discounts	$ 152,972	$ 101,808	$ 0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Revenue	$ 21,306		$ 41,132
Cost of revenue	4,312		4,862
Gross profit	16,994		36,270
Operating expenses	1,052,210	1,035,628	3,163,485	3,770,929	$ 4,603,886	$ 5,410,923
Loss from operations	(1,035,216)	(1,035,628)	(3,127,215)	(3,770,929)	(4,603,886)	(5,410,923)
Other income (expense)
Change in fair value of derivative liability	(3,431,939)	(4,544,656)	(970,760)	(6,945,434)	(2,982,543)	2,853,291
Gain (loss) on settlement of debt	49,806	(58,197)	308,151	2,175,459	80,294	124,888
Gain (loss) on extinguishment of debt					2,485,277	(488,149)
Settlement expenses		(80,000)		(80,000)
Interest expense, net	(1,530,847)	(953,623)	(4,028,129)	(3,958,187)	(5,789,302)	(2,394,779)
Other income (expense)	(4,912,980)	(5,636,476)	(4,690,738)	(8,808,162)	(6,206,274)	95,251
Loss before income taxes	(5,948,196)	(6,672,104)	(7,817,953)	(12,579,091)	(10,810,160)	(5,315,672)
Provision for income taxes
Net loss	$ (5,948,196)	$ (6,672,104)	$ (7,817,953)	$ (12,579,091)	$ (10,810,160)	$ (5,315,672)
Basic and diluted loss per share	$ (0.02)	$ (0.03)	$ (0.02)	$ (0.06)	$ (0.04)	$ (0.05)
Weighted average common shares outstanding:
Basic and diluted	369,234,308	263,535,090	348,379,894	220,353,026	242,090,416	117,405,894

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Operating activities:
Net loss	$ (7,817,953)	$ (12,579,091)	$ (10,810,160)	$ (5,315,672)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization expense	487,474	11,070	14,761	15,833
Fair value of shares issued for services	130,235	1,410,071	1,414,823	2,364,971
Non-cash interest and fees			3,400,511	1,290,383
Gain (loss) on settlement of debt	(308,151)	(2,175,459)	(80,294)	(124,888)
Gain on extinguishment of debt			(2,485,277)	488,149
Amortization of note discount and original issue discount	2,647,939	1,467,888	2,165,710	1,055,316
Amortization of discount on Series C Preferred stock liability	61,912
Non-cash interest expense	623,917	2,465,912
Non-cash value of warrant and stock options issued for services	382,473
Change in fair value of derivative liability	970,760	6,945,434	2,982,543	(2,853,291)
Changes in assets and liabilities:
Accounts receivable	(2,650)
Prepaid expenses and other current assets		156,321	263,321	86,012
Accounts payable and accrued expenses	661,305	108,658	144,292	530,853
Net cash used in operating activities	(2,162,739)	(2,189,196)	(2,989,770)	(2,462,334)
Investing activities:
Acquisition of property and equipment	(8,969)
Acquisition of patents			(3,000,000)
Net cash used in investing activities	(8,969)		(3,000,000)
Financing activities:
Proceeds from the issuance of notes payable	2,336,000	1,562,000	4,047,000	1,491,778
Proceeds from issuance of notes payable- related parties			100,000
Proceeds from related party short-term advances	65,000	12,650
Repayments on related parties short term advances	(87,000)	(11,500)
Proceeds from exercise of warrants			5,050
Proceeds from short term advances			26,000	12,618
Proceeds from issuance of preferred stock	135,000	5	700,005
Repayments on short term advances			(11,500)	(10,300)
Proceeds from issuance of common stock and units	60,000	740,250	1,290,250	1,235,829
Payment against long term loan	(4,221)	(9,263)	(12,395)	(12,031)
Payment against notes payable	(375,500)	(96,000)	(120,000)	(166,500)
Payment on notes payable- related parties				(75,000)
Proceeds from issuance of redeemable shares	617,500
Net cash provided by financing activities	2,746,779	2,198,142	6,024,410	2,476,394
Net increase in cash	575,071	8,946	34,640	14,060
Cash, beginning of year	90,173	55,533	55,533	41,473
Cash, end of period	665,244	64,479	90,173	55,533
Supplemental disclosure of cash flow information:
Cash paid for interest	122,445	27,022	33,868	27,088
Cash paid for Preferred C dividends	37,950
Cash paid for income taxes
Non Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock	1,237,256	1,108,321	1,582,349	711,098
Settlement of liabilities by issuance of common stock			354,964	61,600
Notes payable issued for services				100,000
Notes payable issued on acquisition of patents			1,500,000
Deferred compensation converted to stock options			1,467,311
Accrued interest converted to notes payable			$ 39,570	$ 18,448
Reduction in note payable and accrued interest as result of settlement	82,000
Common stock issued on settlement of debt		289,675
Notes payable and accrued interest exchanged for common stock units		66,367
Value of stock options granted in satisfaction of deferred compensation		$ 1,467,311

Consolidated Statement of Stock

Consolidated Statement of Stockholders Deficit - USD ($)	Series AA Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Stock Subscription Receivable [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2015			$ 10,479	$ 3,773,642	$ (1,570)	$ (13,058,611)	$ (9,276,060)
Balance, shares at Dec. 31, 2015	1,000		104,803,401
Shares issued for cash			$ 566,327	107,022			107,079
Shares issued for cash, shares			57
Units issued for cash			$ 7,968,721	1,127,953			1,128,750
Units issued for cash, shares			797
Share issued for services			$ 990	2,363,981			2,364,971
Share issued for services, shares			9,888,760
Shares issued with notes payable			$ 14	11,066			11,080
Shares issued with notes payable, shares			140,000
Shares issued on extension of notes payable			$ 27	111,634			111,661
Shares issued on extension of notes payable, shares			266,617
Shares issued for conversion of notes payable and accrued interest			$ 947	1,956,770			1,957,717
Shares issued for conversion of notes payable and accrued interest, shares			9,476,582
Units issued for conversion of notes payable and accrued interest			$ 123	308,485			308,608
Units issued for conversion of notes payable and accrued interest, shares			1,226,229
Valuation of warrant and stock options issued for services				40,000			40,000
Net loss						(5,315,672)	(5,315,672)
Balance at Dec. 31, 2016			$ 13,434	9,800,553	(1,570)	(18,374,283)	(8,561,866)
Balance, shares at Dec. 31, 2016	1,000		134,336,637
Units issued for cash	$ 5						5
Units issued for cash, shares	4,000
Private placement units issued for cash			$ 4,242	1,286,008			1,290,250
Private placement units issued for cash, shares			42,434,151
Preferred stock issued for cash							5
Share issued for services			$ 369	203,937			204,306
Share issued for services, shares			3,698,022
Shares issued on exercise of warrants			$ 25	5,025			5,050
Shares issued on exercise of warrants,shares			250,000
Shares issued with lock-up agreements			$ 38	25,232			25,270
Shares issued with lock-up agreements, shares			379,294
Shares issued for conversion of notes payable and accrued interest			$ 12,315	4,963,635			4,975,950
Shares issued for conversion of notes payable and accrued interest, shares			123,163,542
Private placement units issued for conversion of notes payable and accrued interest			$ 400	112,738			113,138
Private placement units issued for conversion of notes payable and accrued interest, shares			4,002,953
Shares issued related to debt extinguishment and settlement			$ 214	119,068			119,282
Shares issued related to debt extinguishment and settlement, shares			2,142,387
Shares issued for repayment of accrued liability			$ 673	235,008			235,681
Shares issued for repayment of accrued liability, shares			6,725,000
Shares returned on settlement of debt			$ (18)	(10,276)			(10,294)
Shares returned on settlement of debt,shares			(180,274)
Valuation of stock options issued for services				1,139,403			1,139,403
Valuation of warrants issued for services				71,113			71,113
Valuation of stock options issued in exchange of deferred compensation				1,467,311			1,467,311
Valuation of warrants issued with note payable				83,453			83,453
Valuation of warrants issued with preferred stock				101,808			101,808
Net loss						(10,810,160)	(10,810,160)
Balance at Dec. 31, 2017	$ 5		$ 31,692	19,604,016	(1,570)	(29,184,443)	(9,550,300)
Balance, shares at Dec. 31, 2017	5,000		316,951,712
Private placement units issued for cash			$ 156	59,844			60,000
Private placement units issued for cash, shares			1,561,950
Preferred stock issued for cash		$ 1		134,999			135,000
Preferred stock issued for cash, shares		1,350
Share issued for services			$ 416	129,819			$ 130,235
Share issued for services, shares			4,150,000				4,150,000
Shares issued with lock-up agreements			$ 2	1,044			$ 1,046
Shares issued with lock-up agreements, shares			17,003
Shares issued for conversion of notes payable and accrued interest			$ 5,870	2,367,869			2,373,739
Shares issued for conversion of notes payable and accrued interest, shares			58,695,192
Valuation of warrant and stock options issued for services				382,473			382,473
Valuation of warrants issued with note payable				71,521			71,521
Valuation of warrants issued with preferred stock				113,076			113,076
Valuation of warrants issued for extension of notes				19,417			19,417
Net loss						(7,817,953)	(7,817,953)
Balance at Sep. 30, 2018	$ 5	$ 1	$ 38,136	$ 22,884,078	$ (1,570)	$ (37,002,396)	$ (14,081,746)
Balance, shares at Sep. 30, 2018	5,000	1,350	381,375,857

Organization and Nature of Busi

Organization and Nature of Business	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Business	Note 1 - Organization and Nature of Business Endonovo Therapeutics, Inc. and Subsidiaries (the “Company” or “ETI”) is primarily focused in the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary non-invasive electroceutical™ device. Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of September 30, 2018 and 2017 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 6, 2018. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. The consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation. Going Concern These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the date these consolidated financial statements are issued. The Company has raised approximately $3,148,500 in debt and equity financing for the period January 1, 2018 to September 30, 2018. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has partially implemented its business plan to materialize revenues from potential, future, license agreements, has initiated a private placement offering to raise capital through the sale of its preferred and common stock and is seeking out profitable companies. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates. Net Income (Loss) per Share Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive. Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 at September 30, 2018 and December 31, 2017. Accounts receivable are written off when all collection attempts have failed. Research and Development Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. In 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments Restricted Cash In 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory On January 1, 2017, we adopted ASU 2016-09, Compensation - Stock Compensation In January 2017, the FASB issued ASU 2017-01, Business Combinations (“ASU 2017-01”) which provided new guidance clarifying the definition of a business for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new standard is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted for transactions that occurred before the issuance date or effective date of the standard if the transactions were not reported in financial statements that have been issued or made available for issuance. Upon early adoption, the standard did not impact how we assess acquisitions (or disposals) of assets or businesses. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) that simplifies the test for goodwill impairment by eliminating step two from the goodwill impairment test. Under the new guidance, an entity should recognize an impairment charge for the amount based on the excess of a reporting unit’s carrying amount over its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. For public companies, the guidance is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019 on a prospective basis, and earlier adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. We early adopted this guidance during the three months ended March 2017, and the adoption did not impact our financial statements. In May 2014, the FASB issued ASU 2014-09 and modified the standard thereafter within Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation—Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. This ASU is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company is currently evaluating the impact of the new guidance on our consolidated financial statements. In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases. The amendments in this Update affect the amendments in Update 2016-02, which are not yet effective, but for which early adoption upon issuance is permitted. For entities that early adopted Topic 842, the amendments are effective upon issuance of this Update, and the transition requirements are the same as those in Topic 842. For entities that have not adopted Topic 842, the effective date and transition requirements will be the same as the effective date and transition requirements in Topic 842. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. Effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this Update. Any entity is permitted to early adopt any removed or modified disclosures upon issuance of this Update and delay adoption of the additional disclosures until their effective date. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements.	Note 1 - Nature of Business and Summary of Significant Accounting Policies Endonovo Therapeutics, Inc. and Subsidiaries (the “Company” or “ETI”) is primarily focused in the business of biomedical research and development, particularly in regenerative medicine, which has included the development of the proprietary non-invasive electrocuetical device and intellectual property licensing and commercialization. On January 22, 2014 Hanover Portfolio Acquisitions, Inc. (the “Company”) received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power of the Company approving an amendment to the Company’s Certificate of Incorporation to change the name of the Company from “Hanover Portfolio Acquisitions, Inc.” to “Endonovo Therapeutics, Inc.” The name change was affected pursuant to a Certificate of Amendment (the “Certificate of Amendment”), filed with the Secretary of State of Delaware on January 24, 2014. Basis of Presentation and Principles of Consolidation The consolidated financial statements of the Company include the accounts of ETI, IP Resources International, Inc., Aviva Companies Corporation, and WeHealAnimals, Inc. All significant intercompany accounts and transactions are eliminated in consolidation. Going Concern These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has recurring net losses, negative cash flows from operations and working capital deficits. The Company has raised approximately $4.4 million in debt and equity financing for the year ended December 31, 2017. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has implemented its business plan to materialize revenues from potential, future, license agreements, has initiated a private placement offering to raise capital through the sale of its common stock and is seeking out profitable companies. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates. Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality institutions. The deposited cash may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. At December 31, 2017, cash and cash equivalents did not exceed FDIC limits. Property, plant and equipment Property, plant and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range between five and seven years. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss recorded to the consolidated statements of operations. Impairment of Long-lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows generated from the asset group to the recorded value of the asset group. If impairment is indicated, the asset is written down to its estimated fair value. Stock-Based Compensation The Company measures stock-based compensation cost at the grant date based on the fair value of the award and recognizes it as expense, net of estimated forfeitures, over the vesting or service period, as applicable, of the stock award using the straight-line method. When our common stock is thinly traded, we have made estimates of the fair value of the common stock based not only on market prices but other factors such as financial condition and results of operations. The Company measured stock-based compensation using the Black-Scholes option valuation model using the following assumptions: December 31, 2017 Expected term 2 - 5 years Exercise price $0.0216 - $0.2669 Expected volatility 184% - 217% Expected dividends None Risk-free interest rate 1.50% - 1.87% Forfeitures None Income Taxes The Company records a tax provision for the anticipated tax consequences of its reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and income tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company has adopted ASC Topic 740, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transition. The Company has determined that the adoption did not result in the recognition of any liability for unrecognized tax benefits and that there are no unrecognized tax benefits that would, if recognized, affect the Company’s effective tax rate. Net Income (Loss) per Share Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive. Research and Development Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development Fair Value of Financial Instruments Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. The Company’s balance sheet contains derivative liability that is recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black-Sholes option valuation model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation. The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2017 and 2016: Fair Value Measurements at December 31, 2017 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 5,939,600 $ 5,939,600 Total $ - $ - $ 5,939,600 $ 5,939,600 Fair Value Measurements at December 31, 2016 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 1,927,752 $ 1,927,752 Total $ - $ - $ 1,927,752 $ 1,927,752 The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2017 and 2016: Liability Balance December 31, 2015 $ 3,973,542 Increase in Derivative Liability resulting from Issuance of convertible debt 2,525,515 Decrease in Derivative Liability resulting from Settlements by debt extinguishment (1,718,013 ) Decrease in Derivative Liability resulting from Change in estimated fair value (2,853,292 ) Balance December 31, 2016 1,927,752 Increase in Derivative Liability resulting from Issuance of convertible debt 9,185,674 Decrease in Derivative Liability resulting from Settlements by debt extinguishment (8,156,369 ) Increase in Derivative Liability resulting from Change in estimated fair value 2,982,543 Balance December 31, 2017 $ 5,939,600 Derivative Liability The Company issued Variable Debentures during the years ended December 31, 2017 and 2016, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This resulted in a derivative liability. The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions: For Year Ending December 31, 2017 2016 Expected term 1 year 1 year - 2 years Exercise price $0.0063-$0.385 $0.0113-$0.81 Expected volatility 163%-201% 176%-276% Expected dividends None None Risk-free interest rate 0.79%-1.76% 0.45%-1.06% Forfeitures None None The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control, and the assessment of volatility. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases. Preferred Stock The Company elects to accrete the difference between the redemption value and carrying value of outstanding preferred stock over the period from the date of issuance to the earliest redemption date using the effective interest method. Recent Accounting Standard Updates In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company does not expect the adoption of this standard to significantly impact its consolidated financial statements. In 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments Restricted Cash In 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory On January 1, 2017, we adopted ASU 2016-09, Compensation - Stock Compensation In January 2017, the FASB issued ASU 2017-01, Business Combinations (“ASU 2017-01”) which provided new guidance clarifying the definition of a business for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new standard is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted for transactions that occurred before the issuance date or effective date of the standard if the transactions were not reported in financial statements that have been issued or made available for issuance. Upon early adoption, the standard did not impact how we assess acquisitions (or disposals) of assets or businesses. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) that simplifies the test for goodwill impairment by eliminating step two from the goodwill impairment test. Under the new guidance, an entity should recognize an impairment charge for the amount based on the excess of a reporting unit’s carrying amount over its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. For public companies, the guidance is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019 on a prospective basis, and earlier adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. We early adopted this guidance during 2017, and the adoption did not impact our financial statements.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2018
Revenue Recognition [Abstract]
Revenue Recognition	2. Revenue Recognition Contracts with Customers We have adopted ASC 606, Revenue from Contracts with Customers . Revenue Recognition We routinely plan on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. Our performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. We identify performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. We generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time we have an unconditional right to receive payment. Our sales and sale prices are final and our prices are not affected by contingent events that could impact the transaction price. Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. In connection with offering products and services provided to the end user by third-party vendors, we review the relationship between us, the vendor and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, we consider whether we act as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction. During the three months ended September 30, 2018, we recognized gross revenue of $21,306 from products we sold as a principal in the transaction. During the nine months ended September 30, 2018, we recognized net revenue of $17,045 from products with a selling price of $43,196 and gross revenue of $24,087 from products we sold as a principal in the transaction. Sources of Revenue We have identified the following revenues disaggregated by revenue source: 1. Plastic Surgeons As of September 30, 2018 and 2017 the sources of revenue were as follows: Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Distributor- Plastic surgeons, net $ - $ - $ 17,045 $ - Direct sales- Plastic surgeons, gross 21,306 - 24,087 - Total sources of revenue $ 21,306 $ - $ 41,132 $ - Warranty Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations. Significant Judgments in the Application of the Guidance in ASC 606 There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon delivery of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary. Practical Expedients Our payment terms for sales direct to distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists. Taxes Collected from Customers Taxes collected on the value of transaction revenue are excluded from product revenues and are accrued in current liabilities until remitted to governmental authorities. Effective Date and Transition Disclosures Adoption of the new standards related to revenue recognition did not have a material impact on our consolidated financial statements.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Note 3 – Property, Plant and Equipment The following is a summary of equipment, at cost, less accumulated depreciation at September 30, 2018 and December 31, 2017: September 30, 2018 December 31, 2017 Autos $ 64,458 $ 64,458 Medical equipment 13,969 5,000 Other equipment 8,774 8,774 87,201 78,232 Less accumulated depreciation 79,460 77,168 $ 7,741 $ 1,064 Depreciation expense for the nine months ended September 30, 2018 and 2017 was $2,292 and $11,070, respectively. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss recorded to the consolidated statements of operations.	Note 2 - Property and Equipment The following is a summary of equipment, at cost, less accumulated depreciation at December 31, 2017 and 2016: As of December 31, 2017 2016 Autos $ 64,458 $ 64,458 Medical equipment 5,000 5,000 Other equipment 8,774 8,774 78,232 78,232 Less accumulated depreciation 77,168 62,407 $ 1,064 $ 15,825 Depreciation expense for the years ended December 31, 2017 and 2016 was $14,761 and $15,833, respectively.

Patents

Patents	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Note 4 – Patents In December 2017, we acquired from Rio Grande Neurosciences, Inc. (RGN) a patent portfolio for $4,500,000 as part of a settlement agreement. The oldest patents expire in 2024. The patent portfolio is amortized through 2024. The following is a summary of patents less accumulated amortization at September 30, 2018 and December 31, 2017: September 30, December 31, 2018 2017 Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 485,183 - $ 4,014,817 $ 4,500,000 Amortization expense associated with patents was $485,183 and $0 for the nine months ended September 30, 2018 and 2017. The estimated future amortization expense related to patents as of September 30, 2018 is as follows: Twelve Months Ending September 30, Amount 2019 $ 646,910 2020 646,910 2021 646,910 2022 646,910 2023 646,910 Thereafter 780,267 Total $ 4,014,817	Note 3 – Patents In December 2017, we acquired from RGN a patent portfolio for $4,500,000 as part of a settlement agreement. The oldest patents expire in 2024. The patent portfolio is amortized through 2024. The following is a summary of patents less accumulated amortization at December 31, 2017 and 2016: December 31, 2017 2016 Patents $ 4,500,000 $ - Less accumulated amortization - - $ 4,500,000 $ - There is no amortization expense associated with patents for the years ended December 31, 2017 and 2016. The estimated future amortization expense related to patents as of December 31, 2017 is as follows: Year Ended December 31. Amount 2018 $ 646,910 2019 646,910 2020 646,910 2021 646,910 2022 646,910 Thereafter 1,265,450 Total $ 4,500,000

Notes Payable and Long Term Loa

Notes Payable and Long Term Loan	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Notes Payable and Long Term Loan	Note 5 - Notes Payable and Long Term Loan Notes Payable During the nine months ended September 30, 2018, the Company issued Convertible Notes (“Variable Notes”) totaling $923,870 for funding of $836,000 with original terms of one year and an interest rate of 10%, and a variable conversion rate with discounts of 35% of the Company’s common stock based on the terms included in the Variable Note. The Variable Notes contains a prepayment option, which enables the Company to prepay the note subsequent to issuance at a premiums of 135%. The Company also issued Fixed Rate Notes (“Fixed Rate Notes”) totaling $1,683,000 for funding of $1,500,000 with original terms of six months and an interest rate ranging from 10% to 12%. The gross amount of all convertible notes with variable conversion rates outstanding at September 30, 2018 is $4,212,620, of which $1,488,750 is past maturity. Notes payable to a related party in the aggregate amount of $270,000 were outstanding at September 30, 2018, of which $100,000 is past maturity. As of September 30, 2018, other notes payable outstanding totaled $3,929,903, of which $1,329,903 is past maturity. September 30, December 31, 2018 2017 Notes payable at beginning of period $ 7,356,144 $ 3,193,956 Notes payable issued 2,606,870 5,837,070 Settlements on note payable (47,500 ) (95,597 ) Repayments of notes payable in cash (375,500 ) (96,000 ) Less amounts converted to stock (1,127,491 ) (1,483,285 ) Notes payable at end of period 8,412,523 7,356,144 Less debt discount (1,175,627 ) (2,624,984 ) $ 7,236,896 $ 4,731,160 Notes payable issued to related parties $ 270,000 $ 270,000 Notes payable issued to non-related parties $ 6,966,896 $ 4,461,160 The maturity dates on the notes payable are as follows: Twelve months ending, Non-related parties Related parties Total Past due $ 2,818,653 $ 100,000 $ 2,918,653 September 30, 2019 5,323,870 170,000 5,493,870 Total $ 8,142,523 $ 270,000 $ 8,412,523	Note 4 - Notes payable and Long Term Loan Notes Payable In October 2013, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000, one unit. The notes bear interest at 10% per annum and were due and payable with accrued interest one year from issuance. Also, the Company agreed to issue 125,000 shares of its common stock for each unit. In July 2014, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000, one unit. The notes bear interest at 10% per annum and were due and payable with accrued interest one year from issuance. Also, the Company agreed to issue 50,000 shares of its common stock for each unit. In October 2014, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000, one unit. The notes bear interest at 10% per annum and were due and payable with accrued interest one year from issuance. Also, the Company agreed to issue 50,000 shares of its common stock for each unit. In August 2015, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000, one unit. The notes bear interest at 10% per annum and were due and payable with accrued interest one year from issuance. Also, the Company agreed to issue 100,000 shares of its common stock for each unit. During the years ended December 31, 2017 and 2016, the Company did not issue notes in connection with these private placements. As of December 31, 2017 and 2016, notes payable outstanding under these private placements are $919,903 and $1,075,500, respectively. Of these amounts, $919,903 and $1,065,000 of the outstanding balance on these notes are past maturity at December 31, 2017 and 2016, respectively. During the years ended December 31, 2017 and 2016, the Company issued Convertible Debentures (“Variable Debentures”) in amounts of $4,137,070 and $1,744,416 for cash of $3,947,000 and $1,421,778 with ori During the year ended December 31, 2017, the Company entered into a $1,500,000 note payable with an unrelated party in connection with the acquisition of patents. The note bears interest at 8% per year and matures in November 2018. At December 31, 2017, $1,500,000 remained outstanding on this note. During the year ended December 31, 2017, the Company entered into a $100,000 note payable with an unrelated party and issued a warrant for up to 500,000 shares of common stock at a value of $21,204 in connection with this note. The note bears interest at 10% per year and matures in February 2018. At December 31, 2017, $100,000 remained outstanding on this note. During the year ended December 31, 2016, the Company entered into two notes payable agreements for $70,000 in aggregate with an unrelated party and issued 140,000 shares in connection with these notes. The notes bear interest at 10% per year and matured in May 2017. At December 31, 2017 and 2016, $0 and $60,000 were outstanding on these notes. As of December 31, 2017, the Company had notes payable to related parties amounting to $270,000. Refer to Note 6 – Related Party Transactions. As of December 31, 2017 2016 Notes payable at beginning of period $ 3,193,956 $ 2,333,751 Notes payable issued 5,837,070 1,776,895 Default interest added to note payable - 62,500 Settlements on note payable (95,597 ) (55,000 ) Repayments of notes payable in cash (96,000 ) (241,500 ) Less amounts converted to stock (1,483,285 ) (682,690 ) Notes payable at end of period 7,356,144 3,193,956 Less debt discount (2,624,984 ) (1,145,849 ) $ 4,731,160 $ 2,048,107 Notes payable issued to related parties $ 270,000 $ 170,000 Notes payable issued to non-related parties $ 4,461,160 $ 1,878,107 The maturity dates on the notes payable are as follows: Twelve months ending, Non-related parties Related parties Total Past due $ 1,122,403 $ 170,000 $ 1,292,403 December 31, 2018 5,963,741 100,000 6,063,741 Total $ 7,086,144 $ 270,000 $ 7,356,144 Long Term Loan The Company has financed the purchase of an automobile. The maturity dates on the loan are as follows: Maturity dates of long term debt Twelve months ending, December 31, 2018 $ 4,221 $ 4,221 Current portion $ 4,221 Acquisition Payable In connection with the Company’s acquisition of IPR in 2012, IPR recorded a $155,000 long-term acquisition payable for costs that were not paid at closing. These payable is non-interest bearing and IPR agreed to make payments up to 25% of the proceeds from any private placement or gross profits earned by IPR until the obligation is satisfied. The percentage of the proceeds to be paid is at the sole discretion of IPR’s Chief Executive Officer and the ex-Chief Executive Officer of the Company based on the liquidity of the Company. Effective Interest Rate During the year ended December 31, 2017 and 2016, the Company’s effective interest rate was 222% and 89%, respectively.

Shareholders' Deficit

Shareholders' Deficit	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Equity [Abstract]
Shareholders' Deficit	Note 6 - Shareholders’ Deficit Increase in Authorized Shares On September 18, 2018, an increase in authorized capital stock from 505,000,000 to 2,505,000,000 became effective, of which 5,000000 shares shall be Preferred Stock, and 2,500,000,000 shall be Common Stock. Preferred Stock The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows: Number of Shares Number of Shares Outstanding at Par Liquidation Authorized September 30, 2018 Value Value Series AA 1,000,000 5,000 $ 0.0001 $ - Preferred Series B 50,000 1,350 $ 0.0001 $ 100 Preferred Series C 8,000 1,318 $ 0.0001 $ 1,000 Undesignated 3,942,000 - - - Series AA Preferred Shares On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.0001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof. Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. The Series AA Super Voting Preferred Stock holders will receive no dividends nor any value on liquidation. As of September 30, 2018, there were 5,000 shares of Series AA Preferred stock outstanding. Series B Convertible Preferred Stock On February 7, 2017, the Company filed a certificate of designation for 50,000 shares of Series B Convertible Preferred Stock designated as Series B (“Series B”) which are authorized and convertible, at the option of the holder, commencing six months from the date of issuance into common shares and warrants. For each share of Series B, the holder, on conversion, shall receive the stated value divided by 75% of the market price on the date of purchase of Series B and a three-year warrant exercisable into up to a like amount of common shares with an exercise price of 150% of the market price as defined in the Certificate of Designation. Dividends shall be paid only if dividends on the Company’s issued and outstanding Common Stock are paid and the amount paid to the Series B holder will be as though the conversion shares had been issued. The Series B holders have no voting rights. Upon liquidation, the holder of Series B, shall be entitled to receive an amount equal to the stated value, $100 per share, plus any accrued and unpaid dividends thereon before any distribution is made to Series C Secured Redeemable Preferred Stock or common stockholders. As of September 30, 2018, 1,350 shares of Series B and 4,805,600 warrant shares have been issued and are outstanding. Series C Secured Redeemable Preferred Stock On December 22, 2017, the Company filed a certificate of designation for 8,000 shares of Series C Secured Redeemable Preferred Stock (“Series C”). Each share of the C Preferred is entitled to receive a $20.00 quarterly dividend commencing March 31, 2018 and each quarter thereafter and is to be redeemed for the stated value, $1,000 per share, plus accrued dividends in cash (i) at the Company’s option, commencing one year from issuance and (ii) mandatorily as of December 31, 2019. The C Preferred does not have any rights to vote with the common stock. Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders but after distributions are made to holders of Series B. Since the C Preferred is mandatorily payable, the obligation has been included in long term liabilities on the consolidated balance sheets as of September 30, 2018 and December 31, 2017. The Company’s obligation to redeem the C Preferred is secured by a security interest in the RGN Assets. As of September 30, 2018, the Company has sold 1,318 shares of C Preferred in units comprised of shares of C Preferred and common stock purchase warrants exercisable into up to 5,996,546 shares of common stock for consideration of $1,317,500. The warrants resulted in a debt discount of $152,972 and $101,808 at September 30, 2018 and December 31, 2017, respectively, and are recorded as a discount to the preferred stock liability on the consolidated balance sheet. Common Stock During the nine months ended September 30, 2018, the Company issued pursuant to a private placement offering 1,561,950 shares of common stock and the same number of warrants for cash of $60,000. The Company also issued 58,695,192 shares of common stock for the conversion of notes and accrued interest in the amount of $1,237,256. During the nine months ended September 30, 2018, the Company issued 17,003 shares of common stock valued at $1,046 related to the extension of outstanding notes and lock-up agreements. During the nine months ended September 30, 2018, the Company issued 4,150,000 shares of common stock with a value of $130,235, related to services and fees. During the nine months ended September 30, 2018, the Company issued 3,387,534 shares of common stock with a value of $116,531 as a commitment to repay a note payable on its stated terms. Since the note was satisfactorily repaid, the shares and commitment fee were rescinded. The Variable Debentures issued by the Company each have a provision requiring the Company to reserve a variable amount of shares of common stock for when the holder of the Variable Debenture converts. Stock Options The balance of all stock options outstanding as of September 30, 2018 is as follows: Weighted Average Weighted Average Exercise Price Remaining Contractual Aggregate Intrinsic Options Per Share Term (years) Value Outstanding at January 1, 2018 93,203,369 $ 0.029 3.96 Granted 1,000,000 $ 0.030 1.86 Cancelled - $ - - Exercised - $ - - Outstanding at September 30, 2018 94,203,369 $ 0.029 3.19 $ 2,232,620 Exercisable at September 30, 2018 93,286,702 $ 0.029 3.21 $ 2,210,895 Warrants During the nine months ended September 30, 2018, in conjunction with the sale of Common Stock, the Company issued three-year common stock purchase warrants to acquire up to 1,561,950 shares of common stock with exercise prices ranging from $0.0734 to $1.00 per share. In addition, during the nine months ended September 30, 2018, the Company issued a five-year common stock purchase warrant to acquire up to 2,000,000 shares of common stock valued at $71,521 with an exercise price of $0.05 in conjunction with the issuance of a note payable; three-year common stock purchase warrants to acquire up to 4,805,600 shares of common stock with exercise prices ranging from $0.051 to $1.00 in conjunction with the issuance of Series B preferred stock; two-year common stock purchase warrants to acquire up to 3,271,277 shares of common stock with exercise prices ranging from $0.0250 to $0.0516 in conjunction with the issuance of Series C preferred stock; a 2-year common stock purchase warrant to acquire up to 6,200,000 shares of common stock valued at $380,750 with an exercise price of $0.0001; and two-year common stock purchase warrants to acquire up to 642,157 shares of common stock with exercise prices ranging from $0.0368 to $0.0370 in conjunction with the extension of certain notes payable. The Company measures the fair value of warrants issued using the Black Scholes option pricing model using the following assumptions: Nine months ended September 30, 2018 Expected term 2 years - 5 years Exercise price $0.0001-$0.0516 Expected volatility 158%-193% Expected dividends None Risk-free interest rate 1.92% to 2.81% Forfeitures None A summary of the status of the warrants granted under these agreements at September 30, 2018, and changes during the nine months then ended is presented below: Outstanding Warrants Weighted Average Exercise Price Shares Per Share Outstanding at January 1, 2018 61,807,992 $ 0.31 Granted 18,480,984 $ 0.20 Cancelled (300,000 ) $ 0.81 Exercised - $ - Outstanding at September 30, 2018 79,988,976 $ 0.28 Exercisable at September 30, 2018 79,988,976 $ 0.28	Note 5 - Shareholders’ Deficit Preferred Stock The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows: Number of Shares Number of Shares Outstanding at Par Liquidation Authorized December 31, 2017 Value Value Series AA 1,000,000 5,000 $ 0.0001 $ - Preferred Series B 50,000 - $ 0.0001 $ 100 Preferred Series C 8,000 700 $ 0.0001 $ 1,000 Undesignated 3,942,000 - - - Series AA Preferred Shares On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.0001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof. Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. Upon liquidation, dissolution and winding up of the Corporation, whether voluntary or involuntary, the holders of the Series AA Super Voting Preferred Stock then outstanding shall not be entitled to receive out of the assets of the Corporation, whether from capital or earnings available for distribution, any amounts which will be otherwise available to and distributed to the Common Stockholders. As of December 31, 2017 and 2016, there were 5,000 and 1,000 shares of Series AA Preferred stock outstanding. Series B Convertible Preferred Stock At December 31, 2017, there are 50,000 shares of Series B Convertible Preferred Stock designated as Series B (“Series B”) which are authorized and convertible into a like amount of common shares. None of the Series B have been issued or are outstanding at December 31, 2017. Series C Secured Redeemable Preferred Stock During the year ended December 31, 2017, the Company filed a certificate of designation (the “Designation”) for 8,000 shares of Series C Secured Redeemable Preferred Stock (“C Preferred”). Each share of the C Preferred, which has a stated value of $1,000 per share and par value of $0.0001 per share, is entitled to a $20.00 quarterly dividend commencing March 21, 2018 and each quarter thereafter and is to be redeemed for the stated value plus accrued dividends in cash (i) at the Company’s option, commencing one year from issuance and (ii) mandatorily as of December 31, 2019. Since the C Preferred is mandatorily payable, the obligation has been included in long term liabilities on the consolidated balance sheet as of December 31, 2017. The C Preferred does not have any rights to vote with the common stock. The Company’s obligation to redeem the C Preferred is secured by a security interest in the RGN Assets. The Preferred Stock Series C holders have liquidation preferences over the common stock holders. As of December 31, 2017, the Company has sold 700 shares of C Preferred in units comprised of shares of C Preferred and common stock purchase warrants exercisable into up to 2,725,269 shares of common stock for consideration of $700,000. The warrants are valued at $101,808 at December 31, 2017 and are recorded as a discount to the preferred stock liability on the consolidated balance sheet. Common Stock During the year ended December 31, 2017, the Company issued pursuant to a private placement offering 46,437,104 shares of common stock and the same number of warrants for cash of $1,290,250 and conversion of notes and accrued interest in the amount of $113,138. The Company also issued 123,163,542 shares of common stock for the conversion of notes and accrued interest in the amount of $4,975,949. During the year ended December 31, 2017, the Company issued 379,294 shares of common stock valued at $25,270 related to the extension of outstanding notes and lock-up agreements; 2,142,387 shares valued at $119,282 were issued in connection with $95,597 notes payable; 6,725,000 shares valued at $235,681 were issued in connection with a settlement entered into in 2016; 250,000 shares were issued for cash of $5,050 as a result of a common stock warrant exercise; and 180,274 shares were cancelled valued at $10,294 related to a settlement agreement. The Company had entered into consulting agreements with various consultants for service to be provided to the Company. The agreements stipulated a monthly fee and a certain number of shares that the consultant vests in over the term of the contract. The consultant was issued a prorated number of shares of common stock at the beginning of the contract, which the consultant earned over a three-month period. At the anniversary of each quarter, the consultant was issued a new allotment of common stock during the first 3 years of engagement. In accordance with ASC 505-50 – Equity-Based Payment to Non-Employees, the common stock shares issued to the consultant were valued upon their vesting, with interim estimates of value as appropriate during the vesting period. During the years ended December 31, 2017 and 2016, the Company issued 3,698,022 shares of common stock with a value of $204,306 and 2,775,000 shares of common stock with a value of $953,250, respectively, related to these consulting agreements. During the year ended December 31, 2016, the Company also issued 7,113,760 shares of common stock with a value of $1,411,722 for additional services and fees. During the year ended December 31, 2016, the Company issued pursuant to a private placement offering 9,194,940 shares of common stock and the same number of warrants for cash of $1,128,750 and conversion of notes and accrued interest in the amount of $308,608. The Company also issued 566,327 shares of common stock for cash of $107,079 and 9,476,582 shares of common stock for the conversion of notes and accrued interest in the amount of $1,957,717. Also, during the year ended December 31, 2016, the Company issued 266,617 shares of common stock valued at $111,661 related to the extension of outstanding notes and lock-up agreements and 140,000 shares valued at $11, 080 were issued in connection with $70,000 notes payable. The Variable Debentures issued by the Company each have a provision requiring the Company to reserve a variable amount of shares of common stock for when the holder of the Variable Debenture converts. As of December 31, 2017, the Company has reserved approximately 147,868,000 of common shares related to the outstanding debentures. Stock Options During the year ended December 31, 2017, the Company granted stock options to independent contractors exercisable into up to 25,272,305 shares of common stock with exercise prices ranging from $0.0269 to $0.054 per share, lives ranging from three to ten years, and cashless exercise rights and were valued at $1,139,403 using the Black Scholes option pricing model. The stock options vested on grant and were expensed in full during the year ended December 31, 2017. In addition, during the year ended December 31, 2017, the Company issued stock options to independent contractors exercisable into up to 67,931,064 shares of common stock in exchange for the conversion of $1,467,311 of deferred compensation due to the independent contractors. These options have an exercise price of $0.0216 per share, a three-year life and cashless exercise rights. These options vested on grant. The weighted average grant date fair value of stock options issued during the year ended December 31, 2017 was $0.03 per share. The balance of all stock options outstanding as of December 31, 2017 is as follows: Weighted Average Weighted Average Exercise Price Remaining Contractual Aggregate Intrinsic Options Per Share Term (years) Value Outstanding at January 1, 2017 - $ - Granted 93,203,369 $ 0.029 Cancelled - $ - Exercised - $ - Outstanding at December 31, 2017 93,203,369 $ 0.029 3.96 $ 2,721,538 Exercisable at December 31, 2017 93,203,369 $ 0.029 3.96 $ 2,721,538 Outstanding Exercisable Weighted Average Weighted Weighted Range of Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life Price Exercisable Price Options $ 0.0540 19,250,000 9.29 $ 0.0540 19,250,000 $ 0.0540 $ 0.0269 6,022,305 2.72 $ 0.0269 6,022,305 $ 0.0269 $ 0.0216 67,931,064 2.55 $ 0.0216 67,931,064 $ 0.0216 93,203,369 3.96 $ 0.029 93,203,369 $ 0.029 Warrants During the year ended December 31, 2017, in conjunction with the sale of Common Stock, the Company issued three-year and five-year common stock purchase warrants to acquire up to 46,437,100 shares of common stock with exercise prices ranging from $0.0188 to $1.00 per share. In addition, during the year ended December 31, 2017, the Company issued two-year common stock purchase warrants to acquire up to 2,300,000 shares of common stock valued at $83,453 with an exercise prices ranging from $0.0508 to $0.25 in conjunction with the issuance of notes payable; five-year common stock purchase warrants to acquire up to 1,100,678 shares of common stock valued at $71,113 for services provided with exercise prices ranging from $0.096 to $0.267 per share; and two-year common stock purchase warrants to acquire up to 2,725,269 shares of common stock with exercise prices ranging from $0.047 to $0.058 in conjunction with the issuance of preferred stock. During the year ended December 31, 2016, in conjunction with the sale of Common Stock, the Company issued five-year common stock purchase warrants to acquire up to 9,194,940 shares of common stock with exercise prices ranging from $0.0825 to $0.90 per share. In March 2016, the Company issued a two-year common stock purchase warrant exercisable into up to 300,000 shares of common stock with an exercise price of $0.81 for services provided by a consultant. The value of these warrants was recorded as non-cash expense in an amount of $40,000 using the Black Sholes Option pricing method. A summary of the status of the warrants granted under these agreements at December 31, 2017, and changes during the year then ended is presented below: Outstanding Warrants Weighted Average Exercise Price Shares Per Share Outstanding at January 1, 2017 9,494,940 $ 0.33 Granted 52,563,052 $ 0.31 Cancelled - $ - Exercised (250,000 ) $ 0.02 Outstanding at December 31, 2017 61,807,992 $ 0.31 Exercisable at December 31, 2017 61,807,992 $ 0.31 Outstanding Exercisable Weighted Average Weighted Weighted Range of Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life Price Exercisable Price Warrants $ 0.0165-0.0469 15,019,850 3.44 $ 0.033 15,019,850 $ 0.033 $ 0.0508-0.10 21,438,396 3.56 $ 0.075 21,438,396 $ 0.075 $ 0.108-0.239 6,010,037 3.60 $ 0.161 6,010,037 $ 0.161 $ 0.25-0.48 2,862,687 2.56 $ 0.276 2,862,687 $ 0.276 $ 0.5623-1.00 16,477,022 2.77 $ 0.938 16,477,022 $ 0.938 61,807,992 3.32 $ 0.313 61,807,992 $ 0.313 As of December 31, 2017, the Company has 500,000,000 shares of common stock authorized. After the exercise of stock options and warrants and the conversion of variable rate debentures, the Company could potentially have a shortfall of common stock. Should there be a shortfall in common stock, the shareholders of the Company would need to approve an increase in the authorized common stock to an amount sufficient to satisfy such exercises and conversions or reclassify the obligations to liabilities payable in some form other than common stock.

Related Party Transactions

Related Party Transactions	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Note 7 – Related Party Transactions One executive of the Company has entered into note payable agreements with the Company. The balance of notes payable from related parties at September 30, 2018 is $270,000. As of September 30, 2018 and December 31, 2017, the balance of executives’ deferred compensation is $942,650 and $922,425, respectively. From time-to-time executives of the Company advance monies to the Company to cover costs. During the nine months ended September 30, 2018, executives advanced $65,000 of funds to the Company and received payments of $87,000 resulting in a $0 balance of short-term advances due to executives at September 30, 2018.	Note 6 – Related Party Transactions Executives of the Company have agreed to defer compensation until cash flow improves. As of December 31, 2017 and 2016, the balances of their deferred compensation was $922,395 and $1,861,327 which reflects $894,394 accrual of deferred compensation, $1,173,297 stock options/warrants and the conversion of $660,000 of deferred compensation into stock options of the Company during the year ended December 31, 2017 and $720,000 accrual of deferred compensation and $533,103 cash repayments during the year ended December 31, 2016. From time-to-time Executives of the Company advance monies to the Company to cover costs. During the years ended December 31, 2017 and 2016, officers advanced $26,000 and $12,618 of funds to the Company of which $11,500 and $10,300 were repaid during the years then ended. Also, during the years ended December 31, 2017 and 2016 accrued interest was repaid in an amount of $22,100 and $0, respectively. The balance of short-term advances Executives of the Company at December 31, 2017 and 2016 was $20,323 and $5,823, respectively. During the years ended December 31, 2017 and 2016, an Executive of the Company entered into note payable agreements for $100,000 and $50,000, respectively. During the year ended December 31, 2016, the Company repaid the principal and interest of a $75,000 note payable to another Executive. At December 31, 2017 and 2016, notes payable remain outstanding to one Executive of the Company, in the amounts of $270,000 and $170,000, respectively. At December 31, 2017 and 2016, accrued interest on these notes payable totaled $21,983 and $20,284, respectively, and are included in accounts payable and accrued expenses on the consolidated balance sheet.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Note 7 - Income taxes The Company files income tax returns with the Internal Revenue Service (“IRS”) and various state jurisdictions. For jurisdictions in which tax filings are prepared, the Company is subject to income tax examinations by state tax authorities and federal tax authorities for all tax years. The deferred tax assets are mainly comprised of net loss carryforwards. As of December 31, 2017, the Company had approximately $14,000,000 of federal net operating loss carryforwards that it can use to offset a certain amount of taxable income in the future. These federal net operating loss carryforwards begin to expire in 2029. The resulting deferred tax asset is offset by a 100% valuation allowance due to the uncertainty of its realization. A reconciliation of the provision for income tax expense with the expected income tax computed by applying the federal statutory income tax rate to income before provision for income taxes was as follows for the years ended December 31, 2017 and 2016: 2017 2016 Income tax computed at federal statutory tax rate -34.0 % -34.0 % Change in valuation allowance 39.8 % 39.8 % State taxes, net of federal benefit -5.8 % -5.8 % Total 0.0 % 0.0 % The primary difference between income tax expense attributable to continuing operations and the amount of income tax expense that would result from applying domestic federal statutory rates to income before provision for income taxes relates to the change in the valuation allowance. The Company has adopted the accounting standards that clarify the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. Interest and penalties totaled $0 for the years ended December 31, 2017 and 2016.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 8 – Fair Value Measurements The Company has issued Variable Debentures which contained variable conversion rates based on unknown future prices of the Company’s common stock. This results in a conversion feature. The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions: Nine months ended September 30, 2018 2017 Expected term 1 month - 1 year 1 month - 1 year Exercise price $0.0129-$0.0326 $0.0085-$0.0385 Expected volatility 119%-195% 189%-201% Expected dividends None None Risk-free interest rate 1.79% to 2.59% 1.03% to 1.31% Forfeitures None None The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases. The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the nine months ended September 30, 2018: Derivative Liability Balance December 31, 2017 $ 5,939,600 Issuance of convertible debt 1,459,645 Settlements by debt settlement (1,312,833 ) Change in estimated fair value 970,760 Balance September 30, 2018 $ 7,057,172 Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. The Company’s balance sheet contains derivative liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black Scholes option pricing model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation. The following table presents balances in the liabilities with significant unobservable inputs (Level 3) at September 30, 2018: Fair Value Measurements Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total As of September 30, 2018 Derivative liability $ - $ - $ 7,057,172 $ 7,057,172 Total $ - $ - $ 7,057,172 $ 7,057,172

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 – Commitments and Contingencies Legal Matters The Company may become involved in various legal proceedings in the normal course of business.	Note 8 - Commitments and Contingencies Legal matters The Company may become involved in various legal proceedings in the normal course of business.

Subsequent Events

Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 10 – Subsequent Events Subsequent to September 30, 2018, an aggregate of 37,001,589 shares of restricted common stock were issued on the conversion of $559,813 of principal and $76,844 of accrued interest pursuant to Variable Notes. Subsequent to September 30, 2018, 575,800 shares of restricted common stock were issued on the conversion of $15,000 of principal and $5,153 of accrued interest pursuant to one Fixed Rate Note and issued 3 year warrants for an exercise of up to 575,800 shares of common stock with exercise prices ranging from $0.069 to $1.00. Subsequent to September 30, 2018, 2,000,000 shares of restricted common stock were issued related to the sale of stock for cash of $25,000 at prices ranging $0.01 to $0.015. Subsequent to September 30, 2018, the Company received $85,000 of cash and retired $317,691 of fixed rate notes and accrued interest for the issuance of 402.7 shares of Preferred C Stock and issuance of two-year warrants for the exercise up to 3,186,104 shares of common stock with exercise prices ranging from $0.0218 to $0.0470. Subsequent to September 30, 2018, 2,025,000 shares of restricted common stock were issued related to services rendered. Subsequent to September 30, 2018, 2,941,176 shares of restricted common stock were issued on the conversion of 750 shares of Preferred B Stock at a conversion rate of $0.0255 per common share. Subsequent to September 30, 2018, 1,000,000 shares of restricted common stock were issued related to the issuance of a $550,000 conditional convertible note payable. The value of the shares were recorded as a discount to the note. Subsequent to September 30, 2018, 6,183,243 shares of restricted common stock were issued on the cashless exercise of 6,200,000 common stock purchase warrant shares. Subsequent to September 30, 2018, 460,396 shares of restricted common stock were issued for lock-up agreements. Subsequent to September 30, 2018, 5,000 shares of Series AA Preferred Shares were issued for cash of $5. Subsequent to September 30, 2018, one note holder of seven convertible notes totaling $1,342,000 principal and $150,129 of accrued interest sold their notes to another note holder. The terms to the Company remained the same as with the original note holder. Subsequent to September 30, 2018, cash of $500,000 was received on the issuance of a six-month $550,000 conditional convertible promissory note with an initial interest rate of 10% increasing to 12%, 14% and 16% on the four, five and six-month anniversary of the note. The note is convertible only on the maturity of the note. Subsequent to September 30, 2018, one investor purchased a $1,500,000 fixed rate secured promissory note in exchange for a $,1500,000 one-year, secured convertible promissory note with an interest rate of 10% issued by another investor. The note is convertible into common stock at 65% of the lowest closing bid price of the common stock for the twenty days previous to conversion. The second note continues to be secured by the assets purchased from RGN. As a result of these issuances, the total number of common shares outstanding is 434,563,601, Preferred B shares outstanding is 600 and Preferred C shares outstanding is 1720.2.	Note 9 - Subsequent Events. Subsequent to December 31, 2017, an aggregate of 100,000 shares of restricted common stock and 6,200,000 common stock purchase warrants were issued as compensation to independent contractors. Subsequent to December 31, 2017, the Company raised $60,000 from 3 investors as part of a Private Placement and issued 1,561,950 shares of restricted common stock and 1,561,950 common stock purchase warrants. Subsequent to December 31, 2017, the Company converted $477,491 of principal and $36,039 of accrued interest in Variable Debentures outstanding at December 31, 2017 through the issuance of 19,327,397 of restricted shares of common stock. Subsequent to December 31, 2017, the Company issued 17,003 of restricted common stock related to lock-up agreements and $195,000 of cash was received from the issuance of 1350 shares of Preferred B and 60 shares of Preferred C Stock. In addition, the Company issued warrants exercisable into up to 5,076,111 shares of common stock related to the issuance of the Preferred B and Preferred C Stock. Subsequent to December 31, 2017, the Company received cash of $625,000 in connection with three notes issued for a total of $705,370 and issued a warrant to purchase up to 2,000,000 shares of common stock related to one of the notes. Under the terms of one of the notes, the Company issued 3,387,534 shares of common stock to the lender which are returnable to the Company if the note is fully repaid or fulfilled by its maturity date. As a result of these issuances the total number of common shares outstanding is 341,345,596, Preferred B shares outstanding is 1350 and Preferred C shares outstanding is 760.

Organization and Nature of Bu_2

Organization and Nature of Business (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of September 30, 2018 and 2017 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 6, 2018. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. The consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation.	Basis of Presentation and Principles of Consolidation The consolidated financial statements of the Company include the accounts of ETI, IP Resources International, Inc., Aviva Companies Corporation, and WeHealAnimals, Inc. All significant intercompany accounts and transactions are eliminated in consolidation.
Going Concern	Going Concern These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the date these consolidated financial statements are issued. The Company has raised approximately $3,148,500 in debt and equity financing for the period January 1, 2018 to September 30, 2018. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has partially implemented its business plan to materialize revenues from potential, future, license agreements, has initiated a private placement offering to raise capital through the sale of its preferred and common stock and is seeking out profitable companies.	Going Concern These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has recurring net losses, negative cash flows from operations and working capital deficits. The Company has raised approximately $4.4 million in debt and equity financing for the year ended December 31, 2017. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has implemented its business plan to materialize revenues from potential, future, license agreements, has initiated a private placement offering to raise capital through the sale of its common stock and is seeking out profitable companies.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.
Cash and Cash Equivalents		Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality institutions. The deposited cash may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. At December 31, 2017, cash and cash equivalents did not exceed FDIC limits.
Property Plant and Equipment		Property, plant and equipment Property, plant and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range between five and seven years. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss recorded to the consolidated statements of operations.
Impairment of Long-lived Assets		Impairment of Long-lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows generated from the asset group to the recorded value of the asset group. If impairment is indicated, the asset is written down to its estimated fair value.
Stock- Based Compensation		Stock-Based Compensation The Company measures stock-based compensation cost at the grant date based on the fair value of the award and recognizes it as expense, net of estimated forfeitures, over the vesting or service period, as applicable, of the stock award using the straight-line method. When our common stock is thinly traded, we have made estimates of the fair value of the common stock based not only on market prices but other factors such as financial condition and results of operations. The Company measured stock-based compensation using the Black-Scholes option valuation model using the following assumptions: December 31, 2017 Expected term 2 - 5 years Exercise price $0.0216 - $0.2669 Expected volatility 184% - 217% Expected dividends None Risk-free interest rate 1.50% - 1.87% Forfeitures None
Income Taxes		Income Taxes The Company records a tax provision for the anticipated tax consequences of its reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and income tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company has adopted ASC Topic 740, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transition. The Company has determined that the adoption did not result in the recognition of any liability for unrecognized tax benefits and that there are no unrecognized tax benefits that would, if recognized, affect the Company’s effective tax rate.
Net Income (Loss) Per Share	Net Income (Loss) per Share Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive.	Net Income (Loss) per Share Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive.
Accounts Receivable	Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 at September 30, 2018 and December 31, 2017. Accounts receivable are written off when all collection attempts have failed.
Research and Development	Research and Development Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development	Research and Development Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development
Fair Value of Financial Instruments		Fair Value of Financial Instruments Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. The Company’s balance sheet contains derivative liability that is recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black-Sholes option valuation model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation. The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2017 and 2016: Fair Value Measurements at December 31, 2017 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 5,939,600 $ 5,939,600 Total $ - $ - $ 5,939,600 $ 5,939,600 Fair Value Measurements at December 31, 2016 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 1,927,752 $ 1,927,752 Total $ - $ - $ 1,927,752 $ 1,927,752 The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2017 and 2016: Liability Balance December 31, 2015 $ 3,973,542 Increase in Derivative Liability resulting from Issuance of convertible debt 2,525,515 Decrease in Derivative Liability resulting from Settlements by debt extinguishment (1,718,013 ) Decrease in Derivative Liability resulting from Change in estimated fair value (2,853,292 ) Balance December 31, 2016 1,927,752 Increase in Derivative Liability resulting from Issuance of convertible debt 9,185,674 Decrease in Derivative Liability resulting from Settlements by debt extinguishment (8,156,369 ) Increase in Derivative Liability resulting from Change in estimated fair value 2,982,543 Balance December 31, 2017 $ 5,939,600
Derivative Liability		Derivative Liability The Company issued Variable Debentures during the years ended December 31, 2017 and 2016, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This resulted in a derivative liability. The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions: For Year Ending December 31, 2017 2016 Expected term 1 year 1 year - 2 years Exercise price $0.0063-$0.385 $0.0113-$0.81 Expected volatility 163%-201% 176%-276% Expected dividends None None Risk-free interest rate 0.79%-1.76% 0.45%-1.06% Forfeitures None None The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control, and the assessment of volatility. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.
Preferred Stock		Preferred Stock The Company elects to accrete the difference between the redemption value and carrying value of outstanding preferred stock over the period from the date of issuance to the earliest redemption date using the effective interest method.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. In 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments Restricted Cash In 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory On January 1, 2017, we adopted ASU 2016-09, Compensation - Stock Compensation In January 2017, the FASB issued ASU 2017-01, Business Combinations (“ASU 2017-01”) which provided new guidance clarifying the definition of a business for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new standard is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted for transactions that occurred before the issuance date or effective date of the standard if the transactions were not reported in financial statements that have been issued or made available for issuance. Upon early adoption, the standard did not impact how we assess acquisitions (or disposals) of assets or businesses. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) that simplifies the test for goodwill impairment by eliminating step two from the goodwill impairment test. Under the new guidance, an entity should recognize an impairment charge for the amount based on the excess of a reporting unit’s carrying amount over its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. For public companies, the guidance is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019 on a prospective basis, and earlier adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. We early adopted this guidance during the three months ended March 2017, and the adoption did not impact our financial statements. In May 2014, the FASB issued ASU 2014-09 and modified the standard thereafter within Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation—Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. This ASU is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company is currently evaluating the impact of the new guidance on our consolidated financial statements. In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases. The amendments in this Update affect the amendments in Update 2016-02, which are not yet effective, but for which early adoption upon issuance is permitted. For entities that early adopted Topic 842, the amendments are effective upon issuance of this Update, and the transition requirements are the same as those in Topic 842. For entities that have not adopted Topic 842, the effective date and transition requirements will be the same as the effective date and transition requirements in Topic 842. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. Effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this Update. Any entity is permitted to early adopt any removed or modified disclosures upon issuance of this Update and delay adoption of the additional disclosures until their effective date. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements.	Recent Accounting Standard Updates In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company does not expect the adoption of this standard to significantly impact its consolidated financial statements. In 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments Restricted Cash In 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory On January 1, 2017, we adopted ASU 2016-09, Compensation - Stock Compensation In January 2017, the FASB issued ASU 2017-01, Business Combinations (“ASU 2017-01”) which provided new guidance clarifying the definition of a business for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new standard is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted for transactions that occurred before the issuance date or effective date of the standard if the transactions were not reported in financial statements that have been issued or made available for issuance. Upon early adoption, the standard did not impact how we assess acquisitions (or disposals) of assets or businesses. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) that simplifies the test for goodwill impairment by eliminating step two from the goodwill impairment test. Under the new guidance, an entity should recognize an impairment charge for the amount based on the excess of a reporting unit’s carrying amount over its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. For public companies, the guidance is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019 on a prospective basis, and earlier adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. We early adopted this guidance during 2017, and the adoption did not impact our financial statements.

Organization and Nature of Bu_3

Organization and Nature of Business (Tables)	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Measured Stock-Based Compensation	The Company measured stock-based compensation using the Black-Scholes option valuation model using the following assumptions: December 31, 2017 Expected term 2 - 5 years Exercise price $0.0216 - $0.2669 Expected volatility 184% - 217% Expected dividends None Risk-free interest rate 1.50% - 1.87% Forfeitures None
Schedule of Balances of Liabilities Measured at Fair Value	The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2017 and 2016: Fair Value Measurements at December 31, 2017 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 5,939,600 $ 5,939,600 Total $ - $ - $ 5,939,600 $ 5,939,600 Fair Value Measurements at December 31, 2016 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 1,927,752 $ 1,927,752 Total $ - $ - $ 1,927,752 $ 1,927,752
Schedule of Changes in the Liabilities with Significant Unobservable Inputs	The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2017 and 2016: Liability Balance December 31, 2015 $ 3,973,542 Increase in Derivative Liability resulting from Issuance of convertible debt 2,525,515 Decrease in Derivative Liability resulting from Settlements by debt extinguishment (1,718,013 ) Decrease in Derivative Liability resulting from Change in estimated fair value (2,853,292 ) Balance December 31, 2016 1,927,752 Increase in Derivative Liability resulting from Issuance of convertible debt 9,185,674 Decrease in Derivative Liability resulting from Settlements by debt extinguishment (8,156,369 ) Increase in Derivative Liability resulting from Change in estimated fair value 2,982,543 Balance December 31, 2017 $ 5,939,600
Schedule of Variable Debentures Black-Scholes Valuation Assumptions	The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions: For Year Ending December 31, 2017 2016 Expected term 1 year 1 year - 2 years Exercise price $0.0063-$0.385 $0.0113-$0.81 Expected volatility 163%-201% 176%-276% Expected dividends None None Risk-free interest rate 0.79%-1.76% 0.45%-1.06% Forfeitures None None

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2018
Revenue Recognition [Abstract]
Schedule of Disaggregated by Revenue Source	As of September 30, 2018 and 2017 the sources of revenue were as follows: Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Distributor- Plastic surgeons, net $ - $ - $ 17,045 $ - Direct sales- Plastic surgeons, gross 21,306 - 24,087 - Total sources of revenue $ 21,306 $ - $ 41,132 $ -

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Summary of Property, Plant and Equipment	The following is a summary of equipment, at cost, less accumulated depreciation at September 30, 2018 and December 31, 2017: September 30, 2018 December 31, 2017 Autos $ 64,458 $ 64,458 Medical equipment 13,969 5,000 Other equipment 8,774 8,774 87,201 78,232 Less accumulated depreciation 79,460 77,168 $ 7,741 $ 1,064	The following is a summary of equipment, at cost, less accumulated depreciation at December 31, 2017 and 2016: As of December 31, 2017 2016 Autos $ 64,458 $ 64,458 Medical equipment 5,000 5,000 Other equipment 8,774 8,774 78,232 78,232 Less accumulated depreciation 77,168 62,407 $ 1,064 $ 15,825

Patents (Tables)

Patents (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents Less Accumulated Amortization	The following is a summary of patents less accumulated amortization at September 30, 2018 and December 31, 2017: September 30, December 31, 2018 2017 Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 485,183 - $ 4,014,817 $ 4,500,000	The following is a summary of patents less accumulated amortization at December 31, 2017 and 2016: December 31, 2017 2016 Patents $ 4,500,000 $ - Less accumulated amortization - - $ 4,500,000 $ -
Schedule of Estimated Future Amortization Expense	The estimated future amortization expense related to patents as of September 30, 2018 is as follows: Twelve Months Ending September 30, Amount 2019 $ 646,910 2020 646,910 2021 646,910 2022 646,910 2023 646,910 Thereafter 780,267 Total $ 4,014,817	The estimated future amortization expense related to patents as of December 31, 2017 is as follows: Year Ended December 31. Amount 2018 $ 646,910 2019 646,910 2020 646,910 2021 646,910 2022 646,910 Thereafter 1,265,450 Total $ 4,500,000

Notes Payable and Long Term L_2

Notes Payable and Long Term Loan (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Schedule of Notes Payable	As of September 30, 2018, other notes payable outstanding totaled $3,929,903, of which $1,329,903 is past maturity. September 30, December 31, 2018 2017 Notes payable at beginning of period $ 7,356,144 $ 3,193,956 Notes payable issued 2,606,870 5,837,070 Settlements on note payable (47,500 ) (95,597 ) Repayments of notes payable in cash (375,500 ) (96,000 ) Less amounts converted to stock (1,127,491 ) (1,483,285 ) Notes payable at end of period 8,412,523 7,356,144 Less debt discount (1,175,627 ) (2,624,984 ) $ 7,236,896 $ 4,731,160 Notes payable issued to related parties $ 270,000 $ 270,000 Notes payable issued to non-related parties $ 6,966,896 $ 4,461,160	As of December 31, 2017 2016 Notes payable at beginning of period $ 3,193,956 $ 2,333,751 Notes payable issued 5,837,070 1,776,895 Default interest added to note payable - 62,500 Settlements on note payable (95,597 ) (55,000 ) Repayments of notes payable in cash (96,000 ) (241,500 ) Less amounts converted to stock (1,483,285 ) (682,690 ) Notes payable at end of period 7,356,144 3,193,956 Less debt discount (2,624,984 ) (1,145,849 ) $ 4,731,160 $ 2,048,107 Notes payable issued to related parties $ 270,000 $ 170,000 Notes payable issued to non-related parties $ 4,461,160 $ 1,878,107
Schedule of Maturity Dates of Notes Payable	The maturity dates on the notes payable are as follows: Twelve months ending, Non-related parties Related parties Total Past due $ 2,818,653 $ 100,000 $ 2,918,653 September 30, 2019 5,323,870 170,000 5,493,870 Total $ 8,142,523 $ 270,000 $ 8,412,523	The maturity dates on the notes payable are as follows: Twelve months ending, Non-related parties Related parties Total Past due $ 1,122,403 $ 170,000 $ 1,292,403 December 31, 2018 5,963,741 100,000 6,063,741 Total $ 7,086,144 $ 270,000 $ 7,356,144
Long-term Debt [Member]
Schedule of Maturity Dates of Notes Payable		The maturity dates on the loan are as follows: Maturity dates of long term debt Twelve months ending, December 31, 2018 $ 4,221 $ 4,221 Current portion $ 4,221

Shareholders' Deficit (Tables)

Shareholders' Deficit (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Equity [Abstract]
Schedule of Preferred Stock	The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows: Number of Shares Number of Shares Outstanding at Par Liquidation Authorized September 30, 2018 Value Value Series AA 1,000,000 5,000 $ 0.0001 $ - Preferred Series B 50,000 1,350 $ 0.0001 $ 100 Preferred Series C 8,000 1,318 $ 0.0001 $ 1,000 Undesignated 3,942,000 - - -	The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows: Number of Shares Number of Shares Outstanding at Par Liquidation Authorized December 31, 2017 Value Value Series AA 1,000,000 5,000 $ 0.0001 $ - Preferred Series B 50,000 - $ 0.0001 $ 100 Preferred Series C 8,000 700 $ 0.0001 $ 1,000 Undesignated 3,942,000 - - -
Schedule of Stock Options Outstanding	The balance of all stock options outstanding as of September 30, 2018 is as follows: Weighted Average Weighted Average Exercise Price Remaining Contractual Aggregate Intrinsic Options Per Share Term (years) Value Outstanding at January 1, 2018 93,203,369 $ 0.029 3.96 Granted 1,000,000 $ 0.030 1.86 Cancelled - $ - - Exercised - $ - - Outstanding at September 30, 2018 94,203,369 $ 0.029 3.19 $ 2,232,620 Exercisable at September 30, 2018 93,286,702 $ 0.029 3.21 $ 2,210,895	The balance of all stock options outstanding as of December 31, 2017 is as follows: Weighted Average Weighted Average Exercise Price Remaining Contractual Aggregate Intrinsic Options Per Share Term (years) Value Outstanding at January 1, 2017 - $ - Granted 93,203,369 $ 0.029 Cancelled - $ - Exercised - $ - Outstanding at December 31, 2017 93,203,369 $ 0.029 3.96 $ 2,721,538 Exercisable at December 31, 2017 93,203,369 $ 0.029 3.96 $ 2,721,538
Schedule of Stock Options Valuation of Assumptions	The Company measures the fair value of warrants issued using the Black Scholes option pricing model using the following assumptions: Nine months ended September 30, 2018 Expected term 2 years - 5 years Exercise price $0.0001-$0.0516 Expected volatility 158%-193% Expected dividends None Risk-free interest rate 1.92% to 2.81% Forfeitures None
Schedule of Warrants Outstanding	A summary of the status of the warrants granted under these agreements at September 30, 2018, and changes during the nine months then ended is presented below: Outstanding Warrants Weighted Average Exercise Price Shares Per Share Outstanding at January 1, 2018 61,807,992 $ 0.31 Granted 18,480,984 $ 0.20 Cancelled (300,000 ) $ 0.81 Exercised - $ - Outstanding at September 30, 2018 79,988,976 $ 0.28 Exercisable at September 30, 2018 79,988,976 $ 0.28	A summary of the status of the warrants granted under these agreements at December 31, 2017, and changes during the year then ended is presented below: Outstanding Warrants Weighted Average Exercise Price Shares Per Share Outstanding at January 1, 2017 9,494,940 $ 0.33 Granted 52,563,052 $ 0.31 Cancelled - $ - Exercised (250,000 ) $ 0.02 Outstanding at December 31, 2017 61,807,992 $ 0.31 Exercisable at December 31, 2017 61,807,992 $ 0.31
Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range		Outstanding Exercisable Weighted Average Weighted Weighted Range of Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life Price Exercisable Price Options $ 0.0540 19,250,000 9.29 $ 0.0540 19,250,000 $ 0.0540 $ 0.0269 6,022,305 2.72 $ 0.0269 6,022,305 $ 0.0269 $ 0.0216 67,931,064 2.55 $ 0.0216 67,931,064 $ 0.0216 93,203,369 3.96 $ 0.029 93,203,369 $ 0.029
Schedule of Warrants Exercise Price Range		Outstanding Exercisable Weighted Average Weighted Weighted Range of Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life Price Exercisable Price Warrants $ 0.0165-0.0469 15,019,850 3.44 $ 0.033 15,019,850 $ 0.033 $ 0.0508-0.10 21,438,396 3.56 $ 0.075 21,438,396 $ 0.075 $ 0.108-0.239 6,010,037 3.60 $ 0.161 6,010,037 $ 0.161 $ 0.25-0.48 2,862,687 2.56 $ 0.276 2,862,687 $ 0.276 $ 0.5623-1.00 16,477,022 2.77 $ 0.938 16,477,022 $ 0.938 61,807,992 3.32 $ 0.313 61,807,992 $ 0.313

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Schedule of Stock Option Valuation Assumptions	The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions: Nine months ended September 30, 2018 2017 Expected term 1 month - 1 year 1 month - 1 year Exercise price $0.0129-$0.0326 $0.0085-$0.0385 Expected volatility 119%-195% 189%-201% Expected dividends None None Risk-free interest rate 1.79% to 2.59% 1.03% to 1.31% Forfeitures None None
Schedule of Changes in Liabilities with Significant Unobservable Inputs	The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the nine months ended September 30, 2018: Derivative Liability Balance December 31, 2017 $ 5,939,600 Issuance of convertible debt 1,459,645 Settlements by debt settlement (1,312,833 ) Change in estimated fair value 970,760 Balance September 30, 2018 $ 7,057,172
Schedule of Balance in Liabilities with Significant Unobservable Inputs	The following table presents balances in the liabilities with significant unobservable inputs (Level 3) at September 30, 2018: Fair Value Measurements Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total As of September 30, 2018 Derivative liability $ - $ - $ 7,057,172 $ 7,057,172 Total $ - $ - $ 7,057,172 $ 7,057,172

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the provision for income tax expense with the expected income tax computed by applying the federal statutory income tax rate to income before provision for income taxes was as follows for the years ended December 31, 2017 and 2016: 2017 2016 Income tax computed at federal statutory tax rate -34.0 % -34.0 % Change in valuation allowance 39.8 % 39.8 % State taxes, net of federal benefit -5.8 % -5.8 % Total 0.0 % 0.0 %

Organization and Nature of Bu_4

Organization and Nature of Business (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Debt and equity financing			$ 3,148,500		$ 4,400,000
Provision for doubtful accounts	$ 0		0		0
Research and development expenses	$ 5,238	$ 75,346	$ 163,073	$ 115,159	$ 115,159	$ 0

Nature of Business and Summary

Nature of Business and Summary of Significant Accounting Policies (Details Narrative) (10K) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Debt and equity financing			$ 3,148,500		$ 4,400,000
Unrecognized tax benefits
Research and development expenses	$ 5,238	$ 75,346	$ 163,073	$ 115,159	$ 115,159	$ 0
Minimum [Member]
Property plant and equipment, estimated useful lives					5 years
Maximum [Member]
Property plant and equipment, estimated useful lives					7 years
Hanover Portfolio Acquisitions, Inc [Member]
Acquisitions description					On January 22, 2014 Hanover Portfolio Acquisitions, Inc. (the "Company") received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power of the Company approving an amendment to the Company's Certificate of Incorporation to change the name of the Company from Hanover Portfolio Acquisitions, Inc. to Endonovo Therapeutics, Inc. The name change was affected pursuant to a Certificate of Amendment (the "Certificate of Amendment"), filed with the Secretary of State of Delaware on January 24, 2014.
Common stock, voting rights					Common Stock representing in excess of 50% of the total issued and outstanding voting power

Nature of Business and Summar_2

Nature of Business and Summary of Significant Accounting Policies - Schedule of Measured Stock-Based Compensation (Details) (10K) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Stock based compensation, expected dividends	0.00%
Stock based compensation, forfeitures	$ 0
Minimum [Member]
Stock based compensation, expected term	2 years
Stock based compensation, exercise price	$ 0.0216
Stock based compensation, expected volatility	184.00%
Stock based compensation, risk-free interest rate	1.50%
Maximum [Member]
Stock based compensation, expected term	5 years
Stock based compensation, exercise price	$ 0.2669
Stock based compensation, expected volatility	217.00%
Stock based compensation, risk-free interest rate	1.87%

Nature of Business and Summar_3

Nature of Business and Summary of Significant Accounting Policies - Schedule of Balances of Liabilities Measured at Fair Value (Details) (10K) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Derivative liability	$ 7,057,172	$ 5,939,600	$ 1,927,752
Total		5,939,600	1,927,752
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Derivative liability
Total
Significant Other Observable Inputs (Level 2) [Member]
Derivative liability
Total
Significant Unobservable Inputs (Level 3) [Member]
Derivative liability	$ 7,057,172	5,939,600	1,927,752
Total		$ 5,939,600	$ 1,927,752

Nature of Business and Summar_4

Nature of Business and Summary of Significant Accounting Policies - Schedule of Changes in the Liabilities with Significant Unobservable Inputs (Details) (10K) - Derivative Liability [Member] - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Liabilities with significant unobservable inputs , beginning balance	$ 1,927,752	$ 3,973,542
Increase in Derivative Liability resulting from Issuance of convertible debt	9,185,674	2,525,515
Decrease in Derivative Liability resulting from Settlements by debt extinguishment	(8,156,369)	(1,718,013)
Decrease/Increase in Derivative Liability resulting from Change in estimated fair value	2,982,543	(2,853,292)
Liabilities with significant unobservable inputs, ending balance	$ 5,939,600	$ 1,927,752

Nature of Business and Summar_5

Nature of Business and Summary of Significant Accounting Policies - Schedule of Variable Debentures Black-Scholes Valuation Assumptions (Details) (10K) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Forfeitures			$ 0
Derivative Liability [Member]
Forfeitures
Expected Term [Member]
Fair value assumptions, measurement input, term			1 year
Expected Term [Member] | Minimum [Member]
Fair value assumptions, measurement input, term	1 month	1 month		1 year
Expected Term [Member] | Maximum [Member]
Fair value assumptions, measurement input, term	1 year	1 year		2 years
Exercise Price [Member] | Minimum [Member]
Fair value assumptions, measurement input, per share			$ 0.0063	$ 0.0113
Exercise Price [Member] | Maximum [Member]
Fair value assumptions, measurement input, per share			$ 0.385	$ 0.81
Expected volatility [Member] | Minimum [Member]
Fair value assumptions, measurement input, percentages			163.00%	176.00%
Expected volatility [Member] | Maximum [Member]
Fair value assumptions, measurement input, percentages			201.00%	276.00%
Expected Dividend [Member]
Fair value assumptions, measurement input, percentages			0.00%	0.00%
Risk Free Interest Rate [Member] | Minimum [Member]
Fair value assumptions, measurement input, percentages			0.79%	0.45%
Risk Free Interest Rate [Member] | Maximum [Member]
Fair value assumptions, measurement input, percentages			1.76%	1.06%

Revenue Recognition (Details Na

Revenue Recognition (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Recognized net revenues	$ 21,306		$ 41,132
Gross Revenue [Member]
Recognized net revenues	$ 21,306		24,087
Product [Member]
Recognized net revenues			17,045
Selling price			$ 43,196

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Disaggregated by Revenue Source (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Total sources of revenue	$ 21,306		$ 41,132
Distributor - Plastic Surgeons Net [Member]
Total sources of revenue			17,045
Direct Sales - Plastic Surgeons Gross [Member]
Total sources of revenue	$ 21,306		$ 24,087

Property, Plant and Equipment_2

Property, Plant and Equipment (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 2,292	$ 11,070	$ 14,761	$ 15,833

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment, gross	$ 87,201	$ 78,232	$ 78,232
Less accumulated depreciation	79,460	77,168	62,407
Property, Plant and Equipment, net	7,741	1,064	15,825
Autos [Member]
Property, Plant and Equipment, gross	64,458	64,458	64,458
Medical Equipment [Member]
Property, Plant and Equipment, gross	13,969	5,000	5,000
Other Equipment [Member]
Property, Plant and Equipment, gross	$ 8,774	$ 8,774	$ 8,774

Property and Equipment (Details

Property and Equipment (Details Narrative) (10K) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 2,292	$ 11,070	$ 14,761	$ 15,833

Patents (Details Narrative)

Patents (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended		12 Months Ended
	Dec. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Acquisition of patents				$ 3,000,000
Amortization expense		$ 485,183	$ 0
Settlement Agreement [Member]
Acquisition of patents				$ 4,500,000	$ 4,500,000
Patents expire period				2,024
Patent amortization description				Patent portfolio is amortized through 2024
Settlement Agreement [Member] | Rio Grande Neurosciences, Inc. [Member]
Acquisition of patents	$ 4,500,000
Patents expire period	2,024
Patent amortization description	Patent portfolio is amortized through 2024

Patents - Schedule of Patents L

Patents - Schedule of Patents Less Accumulated Amortization (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 4,500,000	$ 4,500,000
Less accumulated amortization	485,183
Total	$ 4,014,817	$ 4,500,000

Patents - Schedule of Estimated

Patents - Schedule of Estimated Future Amortization Expense (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
2,019	$ 646,910	$ 646,910
2,020	646,910	646,910
2,021	646,910	646,910
2,022	646,910	646,910
2,023	646,910	646,910
Thereafter	780,267	1,265,450
Total	$ 4,014,817	$ 4,500,000

Patents (Details Narrative) (10

Patents (Details Narrative) (10K) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Acquisition of patents	$ 3,000,000
Settlement Agreement [Member]
Acquisition of patents	$ 4,500,000	$ 4,500,000
Patents expire period	2,024
Patent amortization description	Patent portfolio is amortized through 2024

Notes Payable and Long Term L_3

Notes Payable and Long Term Loan (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Convertible debentures outstanding amount		$ 477,491
Note payable outstanding	$ 6,966,896	4,461,160	$ 1,878,107
Note payable related parties	270,000	270,000	170,000
Past Maturity [Member]
Note payable related parties	100,000
Convertible Debentures [Member]
Convertible debentures outstanding amount	$ 923,870	$ 4,137,070	$ 1,744,416
Debt instrument, interest rates	10.00%	10.00%	10.00%
Debt conversion, converted instrument, rates	35.00%
Percentage of issuance note of premium	135.00%
One Convertible Debentures [Member]
Convertible debentures outstanding amount	$ 836,000
Fixed Rate Note [Member]
Convertible debentures outstanding amount	$ 1,683,000
Fixed Rate Note [Member] | Minimum [Member]
Debt instrument, interest rates	10.00%
Fixed Rate Note [Member] | Maximum [Member]
Debt instrument, interest rates	12.00%
One Fixed Rate Note [Member]
Convertible debentures outstanding amount	$ 1,500,000
Convertible Notes With Variable Conversion Rates [Member]
Note payable outstanding	4,212,620
Convertible Notes With Variable Conversion Rates [Member] | Past Maturity [Member]
Note payable outstanding	1,488,750
Other Notes Payable [Member]
Other notes payable outstanding	3,929,903
Other Notes Payable [Member] | Past Maturity [Member]
Other notes payable outstanding	$ 1,329,903

Notes Payable and Long Term L_4

Notes Payable and Long Term Loan - Schedule of Notes Payable (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Repayments of notes payable in cash	$ (375,500)	$ (96,000)	$ (120,000)	$ (166,500)
Less amounts converted to stock	(2,373,739)		(4,975,950)	(1,957,717)
Notes Payable [Member]
Notes payable at beginning of period	7,356,144	$ 3,193,956	3,193,956	2,333,751
Notes payable issued	2,606,870		5,837,070	1,776,895
Default interest added to note payable				62,500
Settlements on note payable	(47,500)		(95,597)	(55,000)
Repayments of notes payable in cash	(375,500)		(96,000)	(241,500)
Less amounts converted to stock	(1,127,491)		(1,483,285)	(682,690)
Notes payable at end of period	8,412,523		7,356,144	3,193,956
Less debt discount	(1,175,627)		(2,624,984)	(1,145,849)
Note payable, net	7,236,896		4,731,160	2,048,107
Notes payable issued to related parties	270,000		270,000	170,000
Notes payable issued to non-related parties	$ 6,966,896		$ 4,461,160	$ 1,878,107

Notes Payable and Long Term L_5

Notes Payable and Long Term Loan - Schedule of Maturity Dates of Notes Payable (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Past due	$ 2,918,653	$ 1,292,403
September 30, 2019	5,493,870	6,063,741
Total	8,412,523	7,356,144
Non-Related Parties [Member]
Past due	2,818,653	1,122,403
September 30, 2019	5,323,870	5,963,741
Total	8,142,523	7,086,144
Related Parties [Member]
Past due	100,000	170,000
September 30, 2019	170,000	100,000
Total	$ 270,000	$ 270,000

Notes Payable and Long Term L_6

Notes Payable and Long Term Loan (Details Narrative) (10K) - USD ($)	1 Months Ended				9 Months Ended		12 Months Ended
	Aug. 31, 2015	Oct. 31, 2014	Jul. 31, 2014	Oct. 31, 2013	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2012
Proceeds from issuance of note payable					$ 2,336,000	$ 1,562,000	$ 4,047,000	$ 1,491,778
Note payable outstanding					6,966,896		4,461,160	1,878,107
Convertible debentures outstanding amount							477,491
Number of shares issued in connection with note conversions					2,373,739		4,975,950	1,957,717
Warrant to purchase of common stock									300,000
Note payable related parties					270,000		$ 270,000	$ 170,000
Debt effective interest rate							222.00%	89.00%
IPR [Member]
Long-term acquisition payable for costs not paid at closing										$ 155,000
Percentage of proceeds from any private placement or gross profits										25.00%
Two Notes Payable Agreements [Member]
Debt instrument face amount								$ 70,000
Debt instrument, interest rate								10.00%
Note payable outstanding							$ 0	$ 60,000
Debt maturity date								May 31, 2017
Number of shares issued under notes								140,000
Convertible Debentures [Member] | Minimum [Member]
Debt instrument, term							6 months	6 months
Initial principal annual interest rates							6.00%	6.00%
Debt discount rate percentage							25.00%	25.00%
Percentage of issuance note of premium							120.00%	120.00%
Convertible Debentures [Member] | Maximum [Member]
Debt instrument, term							2 years	2 years
Initial principal annual interest rates							10.00%	10.00%
Debt discount rate percentage							53.00%	53.00%
Percentage of issuance note of premium							130.00%	130.00%
Notes Payable [Member]
Note payable outstanding							$ 919,903	$ 1,065,000
Debt discount amount					1,175,627		2,624,984	1,145,849
Number of shares issued in connection with note conversions					$ 1,127,491		1,483,285	682,690
Convertible Debentures [Member]
Debt instrument face amount							$ 3,947,000	$ 1,421,778
Debt instrument, interest rate					10.00%		10.00%	10.00%
Convertible debentures outstanding amount					$ 923,870		$ 4,137,070	$ 1,744,416
Percentage of issuance note of premium					135.00%
Debt discount amount							4,087,500	1,723,471
Number of shares issued in connection with note conversions							48,065,178
Convertible Debentures One [Member]
Convertible debentures outstanding amount							4,566,241	1,888,456
Convertible Debentures Two [Member]
Convertible debentures outstanding amount							202,500	66,000
Notes Payable One [Member]
Debt instrument face amount							$ 1,500,000
Debt instrument, interest rate							8.00%
Note payable outstanding							$ 1,500,000
Debt maturity date							Nov. 30, 2018
Notes Payable Two [Member]
Debt instrument face amount							$ 100,000
Debt instrument, interest rate							10.00%
Note payable outstanding							$ 100,000
Debt maturity date							Feb. 28, 2018
Warrant to purchase of common stock							500,000
Warrant to purchase of common stock, value							$ 21,204
Private Placement [Member]
Debt instrument face amount	$ 500,000	$ 500,000	$ 500,000	$ 500,000
Proceeds from issuance of note payable	$ 25,000	$ 25,000	$ 25,000	$ 25,000
Debt instrument, interest rate	10.00%	10.00%	10.00%	10.00%
Debt instrument, term	1 year	1 year	1 year	1 year
Shares issued for conversion of notes payable and accrued interest, shares	100,000	50,000	50,000	125,000
Note payable outstanding							$ 919,903	$ 1,075,500
Warrant to purchase of common stock							1,561,950

Notes Payable and Long Term L_7

Notes Payable and Long Term Loan - Schedule of Maturity Dates of Notes Payable and Long Term Loan (Details) (10K) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Past due	$ 2,918,653	$ 1,292,403
December 31, 2018	5,493,870	6,063,741
Total	8,412,523	7,356,144
Long-term Debt [Member]
December 31, 2018		4,221
Total		4,221
Current portion		4,221
Non-Related Parties [Member]
Past due	2,818,653	1,122,403
December 31, 2018	5,323,870	5,963,741
Total	8,142,523	7,086,144
Related Parties [Member]
Past due	100,000	170,000
December 31, 2018	170,000	100,000
Total	$ 270,000	$ 270,000

Shareholders' Deficit (Details

Shareholders' Deficit (Details Narrative) - USD ($)	Feb. 22, 2013	Mar. 31, 2016	Aug. 31, 2015	Oct. 31, 2014	Jul. 31, 2014	Oct. 31, 2013	Sep. 30, 2018	Feb. 07, 2018	Dec. 31, 2017	Dec. 31, 2016	Sep. 18, 2018	Dec. 22, 2017	Feb. 07, 2017
Preferred stock, authorized	1,000,000						1,000,000		1,000,000	1,000,000	5,000,000
Common stock, shares authorized							2,500,000,000		2,500,000,000	500,000,000	2,500,000,000
Preferred stock, par value	$ 0.0001						$ 0.001		$ 0.001	$ 0.001
Preferred stock voting rights	Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company.
Preferred stock, outstanding	100,000						5,000		5,000	1,000
Stated value dividend									0.00%
Warrants term		2 years
Preferred stock, shares issued							5,000		5,000	1,000
Warrants issued to purchase common stock		300,000
Shares issued for conversion of notes payable and accrued interest							$ 2,373,739		$ 4,975,950	$ 1,957,717
Issuance of common stock, value							$ 135,000		5
Issuance of common stock related to services and fees, shares							4,150,000
Issuance of common stock related to services and fees							$ 130,235		204,306	2,364,971
Shares issued for commitment fees, shares							3,387,534
Shares issued for commitment fees							$ 116,531
Warrant exercise price		$ 0.81
Notes Payable [Member]
Debt discount							1,175,627		2,624,984	1,145,849
Shares issued for conversion of notes payable and accrued interest							$ 1,127,491		$ 1,483,285	$ 682,690
Lock-Up Agreement [Member]
Common stock, shares issued							17,003		379,294	266,617
Issuance of common stock, value							$ 1,046		$ 25,270	$ 111,661
Private Placement [Member]
Warrants issued to purchase common stock									1,561,950
Shares issued for conversion of notes payable and accrued interest, shares			100,000	50,000	50,000	125,000
Issuance of common stock, value									$ 60,000
Minimum [Member]
Capital stock authorized											505,000,000
Maximum [Member]
Capital stock authorized											2,505,000,000
Series AA Preferred Stock [Member]
Preferred stock, outstanding							5,000		5,000	1,000
Series B Convertible Preferred Stock [Member]
Preferred stock, authorized													50,000
Preferred stock, par value													$ 100
Preferred stock, outstanding							1,350
Stated value dividend								75.00%
Warrants term								3 years
Share exercise price								1.50
Preferred stock, shares issued							1,350
Series C Secured Redeemable Preferred Stock [Member]
Preferred stock, authorized												8,000
Preferred stock dividend per share							$ 20
Shares issued, price per share												$ 1,000
Sale of stock for preferred stock							1,318
Sale of stock, consideration							$ 1,317,500
Debt discount							$ 152,972		$ 101,808
Series C Secured Redeemable Preferred Stock [Member] | Maximum [Member]
Warrants issued to purchase common stock							5,996,546
Common Stock [Member] | Private Placement [Member]
Common stock, shares issued							1,561,950
Number of warrants issued for cash							$ 60,000
Shares issued for conversion of notes payable and accrued interest, shares							58,695,192
Shares issued for conversion of notes payable and accrued interest							$ 1,237,256
Preferred Stock Designated [Member]
Preferred stock, authorized							5,000,000		5,000,000
Warrant [Member]
Preferred stock, outstanding							4,805,600
Stated value dividend							0.00%
Warrants term							3 years			5 years
Preferred stock, shares issued							4,805,600
Warrants issued to purchase common stock							1,561,950			9,194,940
Warrant [Member] | Minimum [Member]
Warrants term									3 years
Warrant exercise price							$ 0.0734			$ 0.0825
Warrant [Member] | Maximum [Member]
Warrants term									5 years
Warrant exercise price							$ 1			$ 0.90
Warrant Two [Member]
Warrants term							5 years		2 years
Warrants issued to purchase common stock							2,000,000		2,300,000
Warrant exercise price							$ 0.05
Warrant value							$ 71,521		$ 83,453
Warrant Two [Member] | Minimum [Member]
Warrant exercise price									$ 0.0508
Warrant Two [Member] | Maximum [Member]
Warrant exercise price									$ 0.25
Warrant Three [Member]
Warrants term							3 years		5 years
Warrants issued to purchase common stock							4,805,600		1,100,678
Warrant value									$ 71,113
Warrant Three [Member] | Minimum [Member]
Warrant exercise price									$ 0.096
Warrant Three [Member] | Maximum [Member]
Warrant exercise price									$ 0.267
Warrant Three [Member] | Series B Convertible Preferred Stock [Member] | Minimum [Member]
Warrant exercise price							$ 0.051
Warrant Three [Member] | Series B Convertible Preferred Stock [Member] | Maximum [Member]
Warrant exercise price							$ 1
Warrant Four [Member]
Warrants term							2 years		2 years
Warrants issued to purchase common stock							3,271,277		2,725,269
Warrant Four [Member] | Minimum [Member]
Warrant exercise price									$ 0.047
Warrant Four [Member] | Maximum [Member]
Warrant exercise price									$ 0.058
Warrant Four [Member] | Series C Preferred Stock [Member] | Minimum [Member]
Warrant exercise price							$ 0.0250
Warrant Four [Member] | Series C Preferred Stock [Member] | Maximum [Member]
Warrant exercise price							$ 0.0516
Warrant Five [Member]
Warrants term							2 years
Warrants issued to purchase common stock							6,200,000
Warrant exercise price							$ 0.0001
Warrant value							$ 380,750
Warrant Six [Member]
Warrants term							2 years
Warrants issued to purchase common stock							642,157
Warrant Six [Member] | Minimum [Member] | Notes Payable [Member]
Warrant exercise price							$ 0.0368
Warrant Six [Member] | Maximum [Member] | Notes Payable [Member]
Warrant exercise price							$ 0.0370

Shareholders' Deficit - Schedul

Shareholders' Deficit - Schedule of Preferred Stock (Details) - USD ($)	Sep. 30, 2018	Sep. 18, 2018	Dec. 31, 2017	Dec. 31, 2016	Feb. 22, 2013
Number of Shares Authorized	1,000,000	5,000,000	1,000,000	1,000,000	1,000,000
Number of Shares Outstanding	5,000		5,000	1,000	100,000
Par Value	$ 0.001		$ 0.001	$ 0.001	$ 0.0001
Series AA [Member]
Number of Shares Authorized	1,000,000		1,000,000
Number of Shares Outstanding	5,000		5,000
Par Value	$ 0.0001		$ 0.0001
Liquidation Value
Preferred Stock B [Member]
Number of Shares Authorized	50,000		50,000
Number of Shares Outstanding	1,350
Par Value	$ 0.0001		$ 0.0001
Liquidation Value	$ 100		$ 100
Preferred Stock C [Member]
Number of Shares Authorized	8,000		8,000
Number of Shares Outstanding	1,318		700
Par Value	$ 0.0001		$ 0.0001
Liquidation Value	$ 1,000		$ 1,000
Undesignated [Member]
Number of Shares Authorized	3,942,000		3,942,000
Number of Shares Outstanding
Par Value
Liquidation Value

Shareholders' Deficit - Sched_2

Shareholders' Deficit - Schedule of Stock Options Outstanding (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Equity [Abstract]
Stock Option Outstanding, Beginning Balance	93,203,369
Stock Option Outstanding, Granted	1,000,000	93,203,369
Stock Option Outstanding, Cancelled
Stock Option Outstanding, Exercised
Stock Option Outstanding, Ending Balance	94,203,369	93,203,369
Stock Option Outstanding, Exercisable	93,286,702	93,203,369
Weighted Average Exercise Price, Beginning Balance	$ 0.029
Weighted Average Exercise Price, Granted	0.030	0.029
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Ending Balance	0.029	0.029
Weighted Average Exercise Price, Exercisable	$ 0.029	$ 0.029
Weighted Average Remaining Contractual Term (years), Outstanding Beginning	3 years 11 months 15 days
Weighted Average Remaining Contractual Term (years), Granted	1 year 10 months 10 days
Weighted Average Remaining Contractual Term (years), Outstanding Ending	3 years 2 months 8 days	3 years 11 months 15 days
Weighted Average Remaining Contractual Term (years), Exercisable	3 years 2 months 16 days	3 years 11 months 15 days
Aggregated Intrinsic Value, Outstanding	$ 2,232,620	$ 2,721,538
Aggregated Intrinsic Value, Exercisable	$ 2,210,895	$ 2,721,538

Shareholders' Deficit - Sched_3

Shareholders' Deficit - Schedule of Stock Options Valuation of Assumptions (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Expected dividends		0.00%
Minimum [Member]
Expected term		2 years
Exercise price		$ 0.0216
Expected volatility		184.00%
Risk-free interest rate		1.50%
Maximum [Member]
Expected term		5 years
Exercise price		$ 0.2669
Expected volatility		217.00%
Risk-free interest rate		1.87%
Warrant [Member]
Expected dividends	0.00%
Forfeitures	0.00%
Warrant [Member] | Minimum [Member]
Expected term	2 years
Exercise price	$ 0.0001
Expected volatility	158.00%
Risk-free interest rate	1.92%
Warrant [Member] | Maximum [Member]
Expected term	5 years
Exercise price	$ 0.0516
Expected volatility	193.00%
Risk-free interest rate	2.81%

Shareholders' Deficit - Sched_4

Shareholders' Deficit - Schedule of Warrants Outstanding (Details) - Warrant [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Shares Outstanding, Beginning Balance	61,807,992	9,494,940
Shares, Granted	18,480,984	52,563,052
Shares, Cancelled	(300,000)
Shares, Exercised		(250,000)
Shares Outstanding, Ending Balance	79,988,976	61,807,992
Shares Exercisable, Ending Balance	79,988,976	61,807,992
Weighted-Average Exercise Price, Outstanding Beginning Balance	$ 0.31	$ 0.33
Weighted-Average Exercise Price, Granted	0.20	0.31
Weighted average exercise price, Cancelled	0.81
Weighted-Average Exercise Price, Exercised		0.02
Weighted-Average Exercise Price, Outstanding Ending Balance	0.28	0.31
Weighted-Average Exercise Price, Exercisable Ending Balance	$ 0.28	$ 0.31

Shareholders' Deficit (Detail_2

Shareholders' Deficit (Details Narrative) (10K) - USD ($)	1 Months Ended					9 Months Ended	12 Months Ended
	Mar. 31, 2016	Aug. 31, 2015	Oct. 31, 2014	Jul. 31, 2014	Oct. 31, 2013	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016	Sep. 18, 2018	Feb. 22, 2013
Preferred stock, authorized						1,000,000	1,000,000	1,000,000	5,000,000	1,000,000
Preferred stock, par value						$ 0.001	$ 0.001	$ 0.001		$ 0.0001
Preferred stock, outstanding						5,000	5,000	1,000		100,000
Preferred stock, shares issued						5,000	5,000	1,000
Warrants issued to purchase common stock	300,000
Private placement units issued for conversion of notes payable and accrued interest							$ 308,608
Issuance of common stock, value						$ 135,000	$ 5
Shares issued with note payable								$ 11,080
Shares issued for cash								$ 107,079
Number of common stock shares issued for additional services and fees							7,113,760
Number of common stock issued for additional services and fees							$ 1,411,722
Reserved common shares							147,868,000
Stock options, grants						1,000,000	93,203,369
Stock options value							$ 1,139,403
Maximum stock options exercisable						93,286,702	93,203,369
Weighted average grant date fair value of stock options
Warrants term	2 years
Warrant exercise price	$ 0.81
Value of warrants	$ 40,000
Common stock, shares authorized						2,500,000,000	2,500,000,000	500,000,000	2,500,000,000
Independent Contractors [Member]
Stock options estimated life term							3 years
Stock options, grants							25,272,305
Maximum stock options exercisable							67,931,064
Converted deferred compensation							$ 1,467,311
Stock options exercise price							$ 0.0216
Weighted average grant date fair value of stock options							$ 0.03
Lock-Up Agreement [Member]
Common stock, shares issued						17,003	379,294	266,617
Issuance of common stock, value						$ 1,046	$ 25,270	$ 111,661
Shares issued with note payable								$ 70,000
Consulting Agreements [Member]
Common stock, shares issued							3,698,022	2,775,000
Issuance of common stock, value							$ 204,306	$ 953,250
Private Placement [Member]
Warrants issued to purchase common stock							1,561,950
Shares issued for conversion of notes payable and accrued interest, shares		100,000	50,000	50,000	125,000
Issuance of common stock, value							$ 60,000
Series AA Preferred Stock [Member]
Preferred stock, outstanding						5,000	5,000	1,000
Series B Convertible Preferred Stock Designated [Member]
Preferred stock, authorized							50,000
Series B Convertible Preferred Stock [Member]
Preferred stock, outstanding
Preferred stock, shares issued
Preferred Stock Designated [Member]
Preferred stock, authorized						5,000,000	5,000,000
Series C Secured Redeemable Preferred Stock Designated [Member]
Preferred stock, authorized							8,000
Series C Secured Redeemable Preferred Stock [Member]
Sale of stock for preferred stock							700
Sale of stock, consideration							$ 700,000
Warrant value							$ 101,808
Series C Secured Redeemable Preferred Stock [Member] | Maximum [Member]
Warrants issued to purchase common stock							2,725,269
Series C Secured Redeemable Preferred Stock [Member] | March 21, 2018 [Member]
Preferred stock, par value							$ 0.0001
Shares issued, price per share							1,000
Preferred stock dividend per share							$ 20
Common Stock [Member]
Common stock, shares issued
Shares issued for conversion of notes payable and accrued interest, shares						58,695,192	123,163,542	9,476,582
Issuance of common stock, value
Shares issued with note payable								$ 14
Shares issued for cash, shares								57
Shares issued for cash								$ 566,327
Common Stock [Member] | Settlement Agreement [Member]
Common stock, shares issued							2,142,387
Issuance of common stock, value							$ 119,282
Shares issued with note payable							$ 95,597
Shares issued with settlement, shares							6,725,000
Shares issued with settlement, value							$ 235,681
Shares issued for cash, shares							250,000
Shares issued for cash							$ 5,050
Number of shares cancelled, shares							180,274
Number of shares cancelled							$ 10,294
Common Stock [Member] | Private Placement [Member]
Common stock, shares issued							46,437,104	9,194,940
Number of warrants issued for cash							$ 1,290,250	$ 1,128,750
Private placement units issued for conversion of notes payable and accrued interest							$ 113,138	$ 308,608
Shares issued for conversion of notes payable and accrued interest, shares							123,163,542	9,476,582
Accrued interest							$ 4,975,949	$ 1,957,717
Shares issued for cash, shares								566,327
Shares issued for cash								$ 107,079
Stock Options [Member]
Range of exercise prices, lower limit							$ 0.0269
Range of exercise prices. Upper limit							$ 0.054
Stock options value							$ 1,139,403
Stock Options [Member] | Maximum [Member]
Stock options estimated life term							10 years
Stock Options [Member] | Minimum [Member]
Stock options estimated life term							3 years
Warrant [Member]
Preferred stock, outstanding						4,805,600
Preferred stock, shares issued						4,805,600
Warrants issued to purchase common stock						1,561,950		9,194,940
Stock options, grants							46,437,100
Range of exercise prices, lower limit							$ 0.0188
Range of exercise prices. Upper limit							$ 1
Warrants term						3 years		5 years
Warrant [Member] | Maximum [Member]
Warrants term							5 years
Warrant exercise price						$ 1		$ 0.90
Warrant [Member] | Minimum [Member]
Warrants term							3 years
Warrant exercise price						$ 0.0734		$ 0.0825
Warrant 2 [Member]
Warrants issued to purchase common stock						2,000,000	2,300,000
Warrant value						$ 71,521	$ 83,453
Warrants term						5 years	2 years
Warrant exercise price						$ 0.05
Warrant 2 [Member] | Maximum [Member]
Warrant exercise price							$ 0.25
Warrant 2 [Member] | Minimum [Member]
Warrant exercise price							$ 0.0508
Warrant 3 [Member]
Warrants issued to purchase common stock						4,805,600	1,100,678
Warrant value							$ 71,113
Warrants term						3 years	5 years
Warrant 3 [Member] | Maximum [Member]
Warrant exercise price							$ 0.267
Warrant 3 [Member] | Minimum [Member]
Warrant exercise price							$ 0.096
Warrant 4 [Member]
Warrants issued to purchase common stock						3,271,277	2,725,269
Warrants term						2 years	2 years
Warrant 4 [Member] | Maximum [Member]
Warrant exercise price							$ 0.058
Warrant 4 [Member] | Minimum [Member]
Warrant exercise price							$ 0.047

Shareholders' Deficit - Sched_5

Shareholders' Deficit - Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range (Details) (10K) - Stock Options [Member]	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Range of exercise prices	$ 0.054
Number of Outstanding outstanding | shares	93,203,369
Weighted average remaining contractual life	3 years 11 months 15 days
Weighted average exercise price	$ 0.029
Number of exercisable | shares	93,203,369
Weighted average exercise price exercisable	$ 0.029
Price Range 1 [Member]
Range of exercise prices	$ 0.0540
Number of Outstanding outstanding | shares	19,250,000
Weighted average remaining contractual life	9 years 3 months 15 days
Weighted average exercise price	$ 0.0540
Number of exercisable | shares	19,250,000
Weighted average exercise price exercisable	$ 0.0540
Price Range 2 [Member]
Range of exercise prices	$ 0.0269
Number of Outstanding outstanding | shares	6,022,305
Weighted average remaining contractual life	2 years 8 months 19 days
Weighted average exercise price	$ 0.0269
Number of exercisable | shares	6,022,305
Weighted average exercise price exercisable	$ 0.0269
Price Range 3 [Member]
Range of exercise prices	$ 0.0216
Number of Outstanding outstanding | shares	67,931,064
Weighted average remaining contractual life	2 years 6 months 18 days
Weighted average exercise price	$ 0.0216
Number of exercisable | shares	67,931,064
Weighted average exercise price exercisable	$ 0.0216

Shareholders' Deficit - Sched_6

Shareholders' Deficit - Schedule of Warrants Exercise Price Range (Details) (10K) - Warrant [Member]	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Range of exercise prices, lower limit	$ 0.0188
Range of exercise prices. upper limit	$ 1
Number of warrants outstanding | shares	61,807,992
Weighted average remaining contractual life	3 years 3 months 26 days
Weighted average exercise price	$ 0.313
Number of warrants exercisable | shares	61,807,992
Weighted average exercise price exercisable	$ 0.313
Price Range 1 [Member]
Range of exercise prices, lower limit	0.0165
Range of exercise prices. upper limit	$ 0.0469
Number of warrants outstanding | shares	15,019,850
Weighted average remaining contractual life	3 years 5 months 9 days
Weighted average exercise price	$ 0.033
Number of warrants exercisable | shares	15,019,850
Weighted average exercise price exercisable	$ 0.033
Price Range 2 [Member]
Range of exercise prices, lower limit	0.0508
Range of exercise prices. upper limit	$ 0.10
Number of warrants outstanding | shares	21,438,396
Weighted average remaining contractual life	3 years 6 months 21 days
Weighted average exercise price	$ 0.075
Number of warrants exercisable | shares	21,438,396
Weighted average exercise price exercisable	$ 0.075
Price Range 3 [Member]
Range of exercise prices, lower limit	0.108
Range of exercise prices. upper limit	$ 0.239
Number of warrants outstanding | shares	6,010,037
Weighted average remaining contractual life	3 years 7 months 6 days
Weighted average exercise price	$ 0.161
Number of warrants exercisable | shares	6,010,037
Weighted average exercise price exercisable	$ 0.161
Price Range 4 [Member]
Range of exercise prices, lower limit	0.25
Range of exercise prices. upper limit	$ 0.48
Number of warrants outstanding | shares	2,862,687
Weighted average remaining contractual life	2 years 6 months 21 days
Weighted average exercise price	$ 0.276
Number of warrants exercisable | shares	2,862,687
Weighted average exercise price exercisable	$ 0.276
Price Range 5 [Member]
Range of exercise prices, lower limit	0.5623
Range of exercise prices. upper limit	$ 1
Number of warrants outstanding | shares	16,477,022
Weighted average remaining contractual life	2 years 9 months 7 days
Weighted average exercise price	$ 0.938
Number of warrants exercisable | shares	16,477,022
Weighted average exercise price exercisable	$ 0.938

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Notes payable - related parties	$ 270,000		$ 270,000	$ 170,000
Repayment of related party debt	87,000	$ 11,500
Executives [Member]
Deferred compensation	942,650		$ 922,425	$ 1,861,327
Related party advances	65,000
Repayment of related party debt	87,000
Short-term advances	$ 0

Related Party Transactions (D_2

Related Party Transactions (Details Narrative) (10K) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Accrual of deferred compensation				$ 720,000
Cash repayment				533,103
Repayment of related party debt	$ 87,000	$ 11,500
Notes payable - related parties	270,000		$ 270,000	170,000
Notes Payable			21,983	20,284
Executives [Member]
Deferred compensation	942,650		922,425	1,861,327
Accrual of deferred compensation			894,394	894,394
Stock options or warrants value			1,173,297	1,173,297
Related party advances	65,000
Repayment of related party debt	$ 87,000
Due to officer			20,323	5,823
Repayment of debt				75,000
Individuals [Member]
Converted deferred compensation			660,000
Executive Officers [Member]
Related party advances			26,000	12,618
Repayment of related party debt			11,500	10,300
Repayment of accrued interest			22,100	0
Executive [Member]
Notes payable - related parties			100,000	50,000
One Executive [Member]
Notes payable - related parties			$ 270,000	$ 170,000

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Stock Option Valuation Assumptions (Details) - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Forfeitures	0.00%	0.00%
Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term			1 year
Measurement Input, Expected Term [Member] | Minimum [Member]
Fair value assumptions, measurement input, term	1 month	1 month		1 year
Measurement Input, Expected Term [Member] | Maximum [Member]
Fair value assumptions, measurement input, term	1 year	1 year		2 years
Measurement Input, Exercise Price [Member] | Minimum [Member]
Fair value assumptions, measurement input, exercise price	$ 0.0129	$ 0.0085
Measurement Input, Exercise Price [Member] | Maximum [Member]
Fair value assumptions, measurement input, exercise price	$ 0.0326	$ 0.0385
Measurement Input, Price Volatility [Member] | Minimum [Member]
Fair value assumptions, measurement input, percentage	119.00%	189.00%
Measurement Input, Price Volatility [Member] | Maximum [Member]
Fair value assumptions, measurement input, percentage	195.00%	201.00%
Measurement Input, Expected Dividend Rate [Member]
Fair value assumptions, measurement input, percentage	0.00%	0.00%
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair value assumptions, measurement input, percentage	1.79%	1.03%
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair value assumptions, measurement input, percentage	2.59%	1.31%

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Changes in Liabilities with Significant Unobservable Inputs (Details)	9 Months Ended
	Sep. 30, 2018USD ($)
Derivative Liability, beginning	$ 5,939,600
Derivative Liability, ending	7,057,172
Significant Unobservable Inputs (Level 3) [Member]
Derivative Liability, beginning	5,939,600
Issuance of convertible debt	1,459,645
Settlements by debt settlement	(1,312,833)
Change in estimated fair value	970,760
Derivative Liability, ending	$ 7,057,172

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Balance in Liabilities with Significant Unobservable Inputs (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Derivative liability	$ 7,057,172	$ 5,939,600	$ 1,927,752
Total	7,057,172
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Derivative liability
Total
Significant Other Observable Inputs (Level 2) [Member]
Derivative liability
Total
Significant Unobservable Inputs (Level 3) [Member]
Derivative liability	7,057,172	$ 5,939,600	$ 1,927,752
Total	$ 7,057,172

Income Taxes (Details Narrative

Income Taxes (Details Narrative) (10K) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Federal net operating loss carry forwards	$ 14,000,000
Federal net operating loss carry forwards expire date	begin to expire in 2029
Deferred tax, valuation allowance percentage	100.00%
Interest and penalties	$ 0	$ 0

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) (10K)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income tax computed at federal statutory tax rate	(34.00%)	(34.00%)
Change in valuation allowance	39.80%	39.80%
State taxes, net of federal benefit	(5.80%)	(5.80%)
Total	0.00%	0.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Oct. 01, 2018	Oct. 01, 2018	Mar. 31, 2016	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Issuance of restricted common stock, value				$ 2,373,739	$ 4,975,950	$ 1,957,717
Warrants term			2 years
Warrant exercise price			$ 0.81
Number of shares issued, value				$ 135,000	$ 5
Warrant to purchase common stock			300,000
Number of shares issued for services				4,150,000
Stock, shares issued				5,000	5,000	1,000
Lock-Up Agreement [Member]
Number of shares issued, value				$ 1,046	$ 25,270	$ 111,661
Number of shares issued				17,003	379,294	266,617
Common Stock [Member]
Issuance of restricted common stock, shares				58,695,192	123,163,542	9,476,582
Issuance of restricted common stock, value				$ 5,870	$ 12,315	$ 947
Number of shares issued, value
Number of shares issued
Number of shares issued for services				4,150,000	3,698,022	9,888,760
Number of shares outstanding				381,375,857	316,951,712	134,336,637	104,803,401
Warrant [Member]
Warrants term				3 years		5 years
Warrant to purchase common stock				1,561,950		9,194,940
Stock, shares issued				4,805,600
Minimum [Member] | Warrant [Member]
Warrants term					3 years
Warrant exercise price				$ 0.0734		$ 0.0825
Maximum [Member] | Warrant [Member]
Warrants term					5 years
Warrant exercise price				$ 1		$ 0.90
Subsequent Event [Member] | Lock-Up Agreement [Member]
Issuance of restricted common stock, shares		460,396
Subsequent Event [Member] | Preferred C Stock [Member]
Number of shares issued, value	$ 85,000
Stock retired during period	$ 317,691
Number of shares issued	402.7
Subsequent Event [Member] | Series AA Preferred Stock [Member]
Stock, shares issued	5,000	5,000
Shares issued price per share	$ 5	$ 5
Subsequent Event [Member] | Common Stock [Member]
Issuance of restricted common stock, shares		2,000,000
Issuance of restricted common stock, value		$ 25,000
Number of shares outstanding	434,563,601	434,563,601
Subsequent Event [Member] | Two Year Warrant One [Member]
Warrants term	2 years
Warrant to purchase common stock	3,186,104	3,186,104
Subsequent Event [Member] | Warrant [Member]
Issuance of restricted common stock, shares		6,183,243
Issuance of restricted common stock, value		$ 6,200,000
Subsequent Event [Member] | Preferred B Stock [Member]
Number of shares outstanding	600	600
Subsequent Event [Member] | Preferred C Stock [Member]
Number of shares outstanding	1,720.2	1,720.2
Subsequent Event [Member] | Minimum [Member] | Common Stock [Member]
Sale of stock price per share	$ 0.01	$ 0.01
Subsequent Event [Member] | Minimum [Member] | Two Year Warrant One [Member]
Warrant exercise price	0.0218	0.0218
Subsequent Event [Member] | Maximum [Member] | Common Stock [Member]
Sale of stock price per share	0.015	0.015
Subsequent Event [Member] | Maximum [Member] | Two Year Warrant One [Member]
Warrant exercise price	$ 0.0470	$ 0.0470
Convertible Note [Member] | Subsequent Event [Member]
Issuance of restricted common stock, shares		1,000,000
Issuance of restricted common stock, value		$ 550,000
Seven Convertible Notes [Member] | Subsequent Event [Member]
Issuance of restricted common stock, shares		1,342,000
Accrued interest		$ 150,129
Conditional Convertible Promissory Note [Member] | Subsequent Event [Member]
Proceeds from issuance of debt		500,000
Debt issuance	$ 550,000	$ 550,000
Debt instrument interest rate	10.00%	10.00%
Conditional Convertible Promissory Note [Member] | Subsequent Event [Member] | Fourth Anniversary [Member]
Debt instrument periodic increase		12.00%
Conditional Convertible Promissory Note [Member] | Subsequent Event [Member] | Fifth Anniversary [Member]
Debt instrument periodic increase		14.00%
Conditional Convertible Promissory Note [Member] | Subsequent Event [Member] | Sixth Anniversary [Member]
Debt instrument periodic increase		16.00%
Secured Promissory Note [Member] | Subsequent Event [Member]
Proceeds from issuance of debt		$ 1,500,000
Debt issuance	$ 1,500,000	$ 1,500,000
Debt instrument interest rate	10.00%	10.00%
Debt Instrument, convertible to common shares percentage		65.00%
Restricted Common Stock [Member] | Subsequent Event [Member]
Issuance of restricted common stock, shares	2,941,176
Number of shares issued for services	2,025,000
Conversion of shares converted	750
Conversion rate price per share	$ 0.0255	$ 0.0255
Restricted Common Stock [Member] | Three Variable Note [Member] | Subsequent Event [Member]
Issuance of restricted common stock, shares	37,001,589
Issuance of restricted common stock, value	$ 559,813
Accrued interest	$ 76,844
Restricted Common Stock [Member] | One Variable Note [Member] | Subsequent Event [Member]
Issuance of restricted common stock, shares	575,800
Issuance of restricted common stock, value	$ 15,000
Accrued interest	$ 5,153
Warrants term	3 years
Restricted Common Stock [Member] | One Variable Note [Member] | Subsequent Event [Member] | Minimum [Member]
Warrant exercise price	$ 0.069	0.069
Restricted Common Stock [Member] | One Variable Note [Member] | Subsequent Event [Member] | Maximum [Member]
Warrant exercise price	$ 1	$ 1

Subsequent Events (Details Na_2

Subsequent Events (Details Narrative) (10K)	Oct. 01, 2018shares	Oct. 01, 2018shares	Aug. 31, 2015shares	Oct. 31, 2014shares	Jul. 31, 2014shares	Oct. 31, 2013shares	Sep. 30, 2018USD ($)shares	Dec. 31, 2017USD ($)Integershares	Dec. 31, 2016USD ($)shares	Mar. 31, 2016shares	Feb. 22, 2013shares
Issuance of restricted common stock, shares								19,327,397
Warrants issued to purchase common stock										300,000
Issuance of common stock, value | $							$ 135,000	$ 5
Convertible debt | $								477,491
Accrued interest | $								$ 36,039
Common stock, shares outstanding							381,375,857	316,951,712	134,336,637
Preferred stock, outstanding							5,000	5,000	1,000		100,000
Three Notes [Member]
Cash received | $								$ 625,000
Warrant value | $								$ 705,370
Common stock, shares outstanding								341,345,596
Preferred Stock B [Member]
Warrants issued to purchase common stock								5,076,111
Issuance of common stock, value | $								$ 1,350
Preferred stock, outstanding							1,350
Preferred Stock B [Member] | Three Notes [Member]
Warrants issued to purchase common stock								5,076,111
Preferred stock, outstanding								1,350
Preferred Stock C [Member]
Issuance of common stock, value | $								$ 60
Preferred stock, outstanding							1,318	700
Preferred Stock C [Member] | Three Notes [Member]
Warrants issued to purchase common stock								5,076,111
Preferred stock, outstanding								760
Lock-Up Agreement [Member]
Issuance of common stock, value | $							$ 1,046	$ 25,270	$ 111,661
Private Placement [Member]
Issuance of restricted common stock, shares								1,561,950
Warrants issued to purchase common stock								1,561,950
Issuance of common stock, value | $								$ 60,000
Number of investors | Integer								3
Number of shares issued to note conversion			100,000	50,000	50,000	125,000
Restricted Common Stock [Member]
Cash received | $								$ 195,000
Restricted Common Stock [Member] | Lock-Up Agreement [Member]
Issuance of restricted common stock, shares								17,003
Restricted Common Stock [Member] | Independent Contractors [Member]
Issuance of restricted common stock, shares								100,000
Warrants issued to purchase common stock								6,200,000
Subsequent Event [Member] | Three Notes [Member]
Number of shares issued to note conversion								3,387,534
Subsequent Event [Member] | One Notes [Member] | Maximum [Member]
Warrants issued to purchase common stock								2,000,000
Subsequent Event [Member] | Lock-Up Agreement [Member]
Number of shares issued to note conversion		460,396
Subsequent Event [Member] | Restricted Common Stock [Member]
Number of shares issued to note conversion	2,941,176